Wearable phototherapy apparatus with anti-viral and other effects

ABSTRACT

Embodiments enables a wearable phototherapy apparatus that produces beneficial effects to a human body such as anti-viral effects, activation of stem cells, improvement in strength, improvement in stamina, pain relief via a non-transdermal container. May include an optional transdermal container that releases or increases copper peptide GHK-Cu in a subject&#39;s body. The non-transdermal apparatus reflects or emits specific wavelengths of light to elevate levels of the copper peptide GHK-Cu in the body. The non-transdermal apparatus includes one or more materials that prevent the Left-Handed molecule from direct contact with the body while the enclosure is coupled to the body and prevents the Left-Handed molecules from entering the body. Embodiments may include or be used with any bioavailable form of copper, e.g., such as copper glycinate as an anti-viral therapy and may include an anti-inflammatory or both.

This application is a continuation-in-part of U.S. Utility patentapplication Ser. No. 16/438,364, filed 11 Jun. 2019, the specificationof which is hereby incorporated herein by reference.

BACKGROUND OF THE INVENTION Field of the Invention

Embodiments of the invention generally relate to a wearable phototherapyapparatus that includes a non-transdermal container with Left-Handedmolecules wherein the container reflects or emits specific wavelengthsof light to stimulate nerves and in some embodiments, also acupuncturepoints. More particularly, but not by way of limitation, in one or moreembodiments, the wearable phototherapy apparatus elevates specificpeptides in a user including GHK, which is also known as tripeptide-1and/or GHK-Cu, which is also known as copper peptide. More particularly,but not by way of limitation, in one or more embodiments, the wearablephototherapy apparatus produces beneficial effects in human beings andanimals, in some embodiments as a result of elevating copper peptide,including anti-viral effects, activation of stem cells, improvements inenergy, elevation of antioxidants, reduction in inflammation, managementof pain, improvements in stamina, elevation of collagen production,improved wound healing and other beneficial health effects, e.g., insome cases as attributed to copper peptide as well as benefitsassociated with stimulating the nerves and in some embodiments, alsoacupuncture points with light. Embodiments may include, or be used withany form of bioavailable copper, for example copper glycinate as ananti-viral therapy and embodiments may include, or be used with ananti-inflammatory or both bioavailable copper and an anti-inflammatory.At least one embodiment may be utilized to treat the novel coronavirus(COVID-19) through light mediated synthesis of copper peptide andmobilization of copper ions for example.

Description of the Related Art

Jewelries including ring, necklace, bracelets, and pendants aretypically used for decorative purpose. However, there is a segment ofthe jewelry market that concerns itself for a purpose other thandecorative. Examples of jewelries that are designed for the purposeother than decorative include copper bracelets and magnetic jewelries.

Copper bracelets are believed to perform functions of relieving pain andhelping to alleviate symptoms of arthritis for a user. A mode ofoperation for these functions has been proposed as mobility of copperions from the copper bracelet through the user's skin and into theuser's blood stream. If the mobility of copper ions is the mode ofoperation of a copper bracelet, then an individual or a user could notobtain immediate relief from pain, etc., due to a long period of timerequired for this mode of operation to become effective. Accordingly, adrawback of existing systems with respect to a copper bracelet is thatthe therapeutic response, if any, takes place over a relatively longperiod of time. Another drawback of the existing systems is that thecopper bracelets have a limited and narrow field of use.

Various types of magnetic jewelries are believed to perform functions ofrelieving pain and improving circulation. Clinical studies performedwith magnetic jewelries indicated that there is an effect going on otherthan a placebo effect. An effect of a magnet on a human body could bedue, in part, to the fact that human blood contains iron. In one theory,the iron in the blood causes the blood to be attracted to a part of thebody in which the magnet is worn, resulting in improvement incirculation. However, there are biophysicists who question the efficacyof a magnetic jewelry. For example, it is well known that the DNAcontains Hydrogen bonds. Because a magnet is polar in nature, a back EMFfrom the magnet to the Hydrogen bonds may be possible. This might causethe hydrogen to spin in opposition to what is normal and disassemble theDNA of that cell. In any case, long term studies of magnets as theyapply to humans are needed. Another drawback of the existing systemswith respect to a magnetic jewelry, is that the therapeutic response, ifany, is limited and narrow with respect to the field of use.

Therefore, with respect to jewelries that may be utilized for thepurpose of achieving a therapeutic effect, there is a need for analternative to the copper bracelet and the magnetic jewelries that arefound in the present market. Such alternative may require a mode ofoperation that is different from the modes of operation of the existingcopper bracelet and magnetic jewelries. In this regard, an examinationof alternative modes of operation for a passive therapeutic jewelryneeds to be considered.

In addition, the body of evidence supporting acupuncture has reached thepoint of being irrefutable. This said, a conclusion may be reached thatin addition to blood flowing through the human body, there is also anenergy flow through the human body.

As an example, in acupuncture, a practitioner utilizes known techniquesto detect “blockages” to energy flows in the human body. When thelocations of these blockages are determined, then either needles orpressure is applied to this point for the purpose of relieving andremoving the blockages. Accordingly, another drawback of the existingsystems is a lack of an apparatus that can be placed over specificacupuncture points and that can interact with a humans' energy field andpromote energy flow and circulation in a similar mode of operation toacupuncture but without needles or physical contact.

Various chemical species in the human body and biochemical materials mayalso need to be considered since they may play a role in interactingwith energy fields within the human body. To this end, Left-Handedmolecules may need to be considered. Generally, the Left-Handed group ofmolecules known as amino acids are utilized in the body for the purposeof building protein structures. This process of the amino acid forming a“building block” for a larger protein structure is generally recognizedas being a solely chemical process, and existing systems lack any otherprocesses that create a buildup of energy to assist in forming a newprotein structure.

Therefore, another drawback of the existing system is a lack of anapparatus and a method for regulating the energy-flow, thereby producinga beneficial response within the human body.

Phototherapy devices currently on the market include things such aslasers, lamps and LED products. These products are typically designed toproduce very specific wavelengths of light. For example, there arephototherapy devices which produce 660 nm light for stimulating energyproduction in the body and increasing collagen production or stimulatinghair growth. In addition, these devices require a power source and arenot disposable.

Generally, there are patches on the market, and most of these aretransdermal devices that deliver drugs or herbs through the skin.

These and other drawbacks also exist in the known art and for thesereasons there is a need for a wearable phototherapy apparatus, forexample that does not require a power source and can be constructed tobe a disposable device, that solves these problems and that produces thebenefits as stated herein.

BRIEF SUMMARY OF THE INVENTION

Embodiments of the invention overcome the problems previously describedabove. In one or more embodiments, the novel apparatus described hereinis designed to reflect or emit specific wavelengths of light that willtrigger the production of copper peptide or elevate other peptides toproduce the benefits associated with the phototherapy devices of theinvention presented herein. In biology this is known asphotobiomodulation. A good example is how UV light will cause theproduct of Vitamin D. This is an example of how light causes changes inthe biochemistry of the body. In one or more embodiments of theinvention, the apparatus, such as a non-transdermal patch, may producebenefits including increasing the metabolism of one or more differentamino acids and elevating neurotransmitters. In at least one embodimentrequires no source of power, unlike conventional phototherapy devicesand may be applied anywhere to the body where treatment is desired.Embodiments may be configured as a disposable device, making it costeffective compared to other phototherapy devices and may be configuredas a non-transdermal patch, wherein no chemicals are based into thebody. In one or more embodiments, stimulation of the skin occurs withlight.

Embodiments may include, or be used with, copper glycinate as ananti-viral therapy or an anti-inflammatory or both. At least oneembodiment may be utilized to treat the novel coronavirus (COVID-19)through light mediated synthesis of copper peptide and mobilization ofcopper ions for example. Benefits of this therapy include:

-   -   Produces rapid alterations in blood chemistry for powerful        antiviral effects    -   Large body of evidence to support efficacy    -   Simple to administer    -   Reduced risk of toxic side effects    -   Inexpensive    -   Large scale manufacturing already in place for immediate        deployment

Embodiments of the invention target viruses through administration ofany form of bioavailable copper, in one embodiment administered orally,in other embodiments via transdermal patches, or via injection, combinedwith embodiments described herein that are configured to light mediatethe synthesis of peptide GHK that binds to copper for producing powerfulantiviral effects. Embodiments may be utilized with anti-inflammatorydrugs, e.g., either taken orally or administered via transdermal patchesor induced by non-transdermal patches for example.

In one embodiment, the invention provides an apparatus or system thatproduces a beneficial effect when placed on a human body. For example,the beneficial effect may include, increasing the metabolism of one ormore amino acids, elevating neurotransmitters, elevation of GHK and/orGHK-Cu, activation of stem cells, improvements in a user's energy,strength increase, stamina increase, pain relief, improved wound healingand other health benefits. In at least one embodiment of the invention,to produce a beneficial effect when placed on a human body, a change inthe biochemistry of the body may be produced via one or more ofproteinogenic amino acids, non-proteinogenic amino acids, L-amino acid,non-standard amino acids, human nutrition and non-protein functions.

In one embodiment, the invention provides an apparatus that produces abeneficial effect when placed on a human body, wherein the apparatus,such as a phototherapy device, provides phototherapy within the humanbody for producing the beneficial effect, for example via anon-transdermal patch.

In one embodiment, the invention provides an apparatus, such as thephototherapy device, that includes biomolecular components and one ormore substrates, for example, but not limited to a polyester, cottonlabor sheet, etc., for the biomolecular components that reflect or emitwavelengths of light for the phototherapy device.

In one embodiment, the invention provides an apparatus includingbiomolecular components associated with reflection of specificwavelengths of light, wherein the biomolecular components may include,for example, but not limited to a Left-Handed molecule such as an aminoacid (e.g., L-Glutamine).

In at least one embodiment of the invention, the system includes a firstlayer that may include a transdermal patch and a second layer that mayinclude a non-transdermal patch. In one or more embodiments, the firstlayer consists essentially of copper peptide GHK-Cu and other materialsthat are known in the art of transdermal patches such as adhesive, suchthat the first layer may deliver the copper peptide GHK-Cu into thesubject's body. In at least one embodiment of the invention, the systemincludes a second layer coupled to the first layer, wherein the secondlayer includes a non-transdermal container having at least oneLeft-Handed material and/or materials capable of reflecting or emittingwavelengths of light capable of activating receptors in the body thatincrease production of GHK and/or GHK-Cu, water, and any necessarypreservatives such as glycerol. In one or more embodiments, the secondlayer may include a plurality of Left-Handed material containerssimultaneously applied to the subject's body.

By way of at least one embodiment, the second layer is coupled on top ofthe first layer, i.e., away from the skin of the user.

In one or more embodiments of the invention, the first layer is directlycoupled to the second layer side by side. In at least one embodiment,the first layer is indirectly coupled to the second layer, such that thefirst layer attaches to a first portion of the subject's body and thesecond layer attaches to a second portion of the subject's body.

According to at least one embodiment of the invention, the first layermay deliver chemicals and nutrients to the subject's body, and thesecond layer does not deliver such chemicals and nutrients to thesubject's body, for example when applied simultaneously.

In one embodiment, the invention provides an apparatus including one ormore substrates, for example, but not limited to a polyester, cottonlabor sheet, etc., for biomolecular components that reflect or emitwavelengths of light for the phototherapy device.

In one embodiment, the invention provides an apparatus including asealed plastic enclosure, wherein the sealed plastic enclosure mayenclose biomolecular components that reflect or emit wavelengths oflight for the phototherapy device.

In one embodiment, the invention provides an apparatus that includes asealed plastic enclosure having biomolecular components that reflect oremit wavelengths of light for the phototherapy device, wherein theapparatus may further include water and preservatives.

In one embodiment, the invention provides one or more physicalstructural settings for holding components of an apparatus. In someembodiments, said one or more physical structural settings may holdbiomolecular components that reflect or emit wavelengths of light forthe phototherapy device, one or more substrates for said biomolecularcomponents, water and preservatives.

In one embodiment, the invention provides an apparatus that produces abeneficial effect, for example elevation of GHK and/or GHK-Cu foractivation of stem cells, when placed on a human body, wherein theapparatus may comprise one or more of components including, for example,Left-Handed molecules (e.g., L-Glutamine), one or more materials thatreflect or emit wavelengths of light capable of elevating GHK and/orGHK-Cu, one or more substrates (e.g., a polyester, cotton fabric sheet,etc.) for said Left-Handed molecules, a sealed enclosure (e.g., plasticfilm enclosure) enclosing said Left-Handed molecules and said one ormore substrates, water and preservatives. One or more embodiments arepackaged as non-transdermal patches for example.

By way of one or more embodiments, Left-Handed group of molecules, suchas amino acids, may be utilized in the body to build protein structuressuch as muscle tissue. At least one embodiment of the invention includesa Left-Handed (such as amino acids that are isomers and present opticalchirality) material-containing apparatus, for example an L-amino acid,wherein light passing through an amino acid will bend to the left, andone or more materials that reflect or emit wavelengths of light capableof elevating GHK and/or GHK-Cu. Accordingly, in one or more embodiments,at the molecular level, in the process of the amino acid being used toform a protein, one or more materials that reflect or emit wavelengthsof light capable of elevating GHK and/or GHK-Cu, or other peptides andbiochemical that produce the benefits discussed herein.

By way of at least one embodiment, the left-handed material-containingapparatus includes materials specifically pre-selected because suchmaterials may interact with the infrared heat (light) being emitted bythe human body, and thus stimulate the materials inside the patchcausing them to reflect specific wavelengths of light back to the body(phototherapy). In one or more embodiments, a packet of photons, such asone packet or small amounts of light, may stimulate a human receptor toactivate the receptor, such that only very small amounts of energy arerequired to cause the photobiomodulation effect.

By way of one or more embodiments, the non-transdermal patch may includetwo phototherapy layers as a first phototherapy layer and a secondphototherapy layer. In at least one embodiment, the first phototherapylayer and the second phototherapy layer are layered and coupled on topof each other, such that one layer of the two phototherapy layers islayered and coupled on top of a second layer of the two phototherapylayers. In one or more embodiments, the first phototherapy layer and thesecond phototherapy layer are layered and coupled as concentric rings.In one or more embodiments, for example, the first phototherapy layerand the second phototherapy layer may be placed next to one another andcoupled directly or indirectly. In at least one embodiment, via the twophototherapy layers, the non-transdermal patch reflects differentwavelengths of light from each layer of the first phototherapy layer andthe second phototherapy layer, therefore producing additional beneficialbiological effects.

According to one or more embodiments, the phototherapy apparatus maydeliver ingredients to the subject's body that complement the functionof GHK-Cu, via one or more patches or layers. In at least oneembodiment, the ingredients may include minerals such as copper, zinc,selenium, magnesium and sulphur, wherein such ingredients support woundhealing and thus provide an advantage to the subject's body.

In one embodiment, the invention provides an apparatus that may be inone or more of a plurality of wearable objects such as, but not limitedto, dermal patches, bracelets, pendants, support pads, shirts, socks,foot inserts, etc.

In some embodiments, the invention provides a non-transdermal patchhaving Left-Handed molecules for improving strength/stamina for a user.

In one embodiment, the invention provides a method for placing anapparatus on a human body or into a human body, wherein the apparatusproduces a beneficial effect when placed on the human body or into thehuman body, wherein the apparatus includes biomolecular componentsassociated with reflection of specific wavelengths of light, wherein thebiomolecular components may include, for example, but not be limited toa Left-Handed molecule such as an amino acid (e.g., L-Carnitine).

In at least one embodiment of the invention, the method includesapplying the first layer to the subject's body and applying the secondlayer to the subject's body.

By way of one or more embodiments, the non-transdermal patch may includeat least one ball or bead. In at least one embodiment, the at least oneball or bead may be or may include plastic. In one or more embodiments,the at least one ball or bead may be located at the bottom of thenon-transdermal patch, such as underneath the non-transdermal patch atan outer surface of the non-transdermal patch. In at least oneembodiment, the at least one ball or bead may be located underneath thenon-transdermal patch, wherein the at least one ball or bead directly orindirectly contacts the user's skin. In one or more embodiments, the atleast one ball or bead may be located between layers of thenon-transdermal patch, such as for example between the first layer andthe second layer of the non-transdermal patch. By way of at least oneembodiment, the at least one ball or bead may stimulate the user's skinwith mild pressure. According to one or more embodiments of theinvention, the at least one ball or bead may stimulate specific pointson the user's skin to provide additional beneficial biological effects,such as to mobilize stem cells of the user.

Other objects and features will become apparent from the followingdetailed description considered in connection with the accompanyingdrawings that disclose embodiments of the invention. It should beunderstood, however, that the drawings are designed for purposes ofillustration only and not as a definition of the limits of theinvention.

BRIEF DESCRIPTION OF THE DRAWINGS

The above and other aspects, features and advantages of at least oneembodiment of the invention will be more apparent from the followingmore particular description thereof, presented in conjunction with thefollowing drawings, wherein:

FIG. 1 illustrates temperature differential in a human body, wherein theapparatus may be applied to any portion of the human body.

2A illustrates an example of an apparatus including a single layerfabric substrate for retaining biomolecular components, according to anembodiment of the invention.

FIG. 2B illustrates an example of a sealed apparatus including a singlelayer fabric substrate for retaining biomolecular components, accordingto an embodiment of the invention.

FIG. 3A illustrates an example of an apparatus including a multi-layerfabric substrate for retaining biomolecular components, according to anembodiment of the invention.

FIG. 3B illustrates an example of a sealed apparatus including amulti-layer fabric substrate for retaining biomolecular components,according to an embodiment of the invention.

FIG. 4 illustrates an example of a patch including a biomolecularapparatus that causes a beneficial effect within a human body, accordingto an embodiment of the invention, and that may contain anon-transdermal apparatus.

FIG. 5 illustrates an example of a bracelet including a biomolecularapparatus that causes a beneficial effect within a human body, accordingto an embodiment of the invention, and that may contain anon-transdermal apparatus.

FIG. 6 illustrates an example of a ring including a biomolecularapparatus that causes a beneficial effect within a human body, accordingto an embodiment of the invention, and that may contain anon-transdermal apparatus.

FIG. 7 illustrates an example of a watch including a biomolecularapparatus that causes a beneficial effect within a human body, accordingto an embodiment of the invention, and that may contain anon-transdermal apparatus.

FIG. 8A illustrates a system that includes a first layer, and a secondlayer with a material-containing apparatus coupled on top of the firstlayer, according to one or more embodiments of the invention.

FIG. 8B illustrates a system that includes a first layer, and a secondlayer with a material-containing apparatus directly coupled to the firstlayer side by side, according to one or more embodiments of theinvention.

FIG. 8C illustrates a system that includes a first layer, and a secondlayer with a material-containing apparatus indirectly coupled to thefirst layer side by side, according to one or more embodiments of theinvention.

FIG. 8D illustrates a system that includes a first layer, and a secondlayer with a material-containing apparatus layered as concentric rings,according to one or more embodiments of the invention.

FIG. 9A illustrates an example of a patch including a system that causesa beneficial effect within a human body, according to an embodiment ofthe invention that contain at least one material that produces aphotobiomodulation effect, and that may contain at least anon-transdermal apparatus and transdermal apparatus.

FIG. 9B illustrates an example of a bracelet including a system thatcauses a beneficial effect within a human body, according to anembodiment of the invention, and that may contain at least anon-transdermal apparatus and transdermal apparatus.

FIG. 9C illustrates an example of a ring including a system that causesa beneficial effect within a human body, according to an embodiment ofthe invention, and that may contain at least a non-transdermal apparatusand transdermal apparatus.

FIG. 9D illustrates an example of a watch including a system that causesa beneficial effect within a human body, according to an embodiment ofthe invention, and that may contain at least a non-transdermal apparatusand transdermal apparatus.

FIG. 10A illustrates a patch with at least one ball or bead locatedunderneath the patch at an outer surface of the patch, according to oneor more embodiments of the invention.

FIG. 10B illustrates a patch with at least one ball or bead locatedbetween layers of the patch, according to one or more embodiments of theinvention.

FIG. 11 illustrates an increase in production of Glutathione thatsupports the reduction of inflammation pathways that enablesdetoxification of the blood to act as an indirect anti-inflammatoryagent.

DETAILED DESCRIPTION OF THE INVENTION

The following description is of the best mode presently contemplated forcarrying out at least one embodiment of the invention. This descriptionis not to be taken in a limiting sense, but is made merely for thepurpose of describing the general principles of the invention. The scopeof the invention should be determined with reference to the claims.

According to at least one embodiment, the invention provides anapparatus that produces a beneficial effect when placed on a human body,wherein the apparatus at least provides phototherapy to the human bodyfor producing the beneficial effect. In one or more embodiments, thebeneficial effect may include, for example, strength increase, staminaincrease, and pain relief. At least one embodiment of the inventionprovides an apparatus that includes a sealed plastic enclosure havingbiomolecular components that reflect or emit wavelengths of light forthe phototherapy device, wherein the apparatus may further include waterand preservatives.

According to at least one embodiment, the invention provides anapparatus that may include orthomolecular organic compounds (e.g.,naturally occurring organic compounds) and or non-orthomolecular organiccompounds for inducing one or more beneficial effects such as, forexample, strength increase, stamina increase, pain relief, etc.

In at least one embodiment, in humans, an increase in electron flow hasnumerous demonstrable benefits with one being an immediate andmeasurable increase in physical strength. By way of one or moreembodiments, this is not a chemically induced increase in strength suchas would be the case with anabolic steroids, etc., but rather aphenomenon in which existing muscle mass is utilized more efficientlydue to the increase in electron flow.

For example, by way of one or more embodiments, when examining thestriated skeletal muscle apparatus, we know that this voluntary groupnerve supply is under conscious control because these nerves arebranches of the peripheral cerebrospinal nervous apparatus (the brainand spinal cord as the cerebrospinal axis). In at least one embodiment,the muscle fibers themselves are tissues composed of contractile cellsthat effect movement based on the excitatory process set up in nervefibers by stimuli (the nerve impulse). It is presently believed bymedical research that the nerve impulse is probably in the nature of awave of electrochemical disturbances. In at least one embodiment, theefficiency with which the nerve impulse controls a specific muscle groupcan be defined as the number of muscle fibers utilized in a contractiondivided by the number of fibers present in that muscle group. It ispresently believed, according to one or more embodiments of theinvention, that most humans only contract a small percentage of musclefibers in a given group for a given nerve impulse (low efficiency ofmuscle mass usage per nerve impulse contraction).

According to one or more embodiments, when inducing a condition in whichthe total power of the electrochemical nerve impulse could be increasedsuch that more muscle fibers could contract for a given nerve impulse,the net efficiency of the striated fibers would increase (more musclefibers in a group being contracted for a nerve impulse), and henceusable physical strength could be improved. As such, by way of one ormore embodiments, the beneficial effects are present, for example,immediate and demonstrable increases in strength and stamina withinseconds of wearing the wearable apparatus according to one or moreembodiments of the invention.

For example, by way of at least one embodiment, in physical therapyelectrical signals are utilized for the purpose of forcing voluntarymuscle groups to contract under stimulation. These devices are commonlyknown as electrical or electronic muscle stimulators (EMS) and causestimulated contraction and relaxation phases of muscle groups. Accordingto at least one embodiment, the invention provides an apparatus for,based on the mode of operation as presented, an improvement in netefficiency of total muscle mass utilized during a contraction phase thatmay be achieved due to an increase in electron flow during the wave ofelectrochemical disturbances created by the nerve impulse.

To understand this occurrence, the metabolic process involving fattyacid energy sources within the human body can be examined. In at leastone embodiment, fatty acids, a hydrocarbon in which one of the hydrogenatoms has been replaced by a carboxyl group, are also described as amonobasic aliphatic acid made up of an alkyl radical attached to acarboxyl group. The metabolic role of fatty acids may be described inpart in that fatty acids are one of the primary sources of energy forhumans and, through Beta-Oxidation, are broken down into basic units ofenergy. Of interest here is that, in one or more embodiments, in orderfor this process to work, fatty acids need to enter the mitochondria forBeta-Oxidation, and they are unable to penetrate the inner mitochondrialmembrane by themselves. In the human body, in at least one embodiment,to overcome the problem of the inability of fatty acids to transportfrom the cytosol (soluble portion of the cell) across the mitochondrialmembrane, it has been determined by several researchers that variousnutrients are essential to transport long chain fatty acids from thecytosol across the mitochondrial membrane for fatty acidoxidation/metabolism and energy production.

According to one or more embodiments of the invention, in order toobtain the desirable effect of improving cell metabolism passively(specifically, increasing the rate of fatty acid Beta-Oxidation byallowing fatty acids to transport across the mitochondrial membrane), anapparatus includes orthomolecular organic structures can be designed topassively interact with the human body.

According to at least one embodiment of the invention, which may be wornanywhere on the human body as shown in FIG. 1, an apparatus 100 (asshown in FIGS. 2B and 3B) that causes a beneficial effect at least byproviding phototherapy to a human body and for example in someembodiments as a result of elevating copper peptide, includingactivation of stem cells, improvements in energy, elevation ofantioxidants, reduction in inflammation, management of pain,improvements in stamina, elevation of collagen production, improvedwound healing.

According to at least one embodiment, the invention provides apparatus100 comprising biomolecular components that may include moleculesassociated with building-up of energy. In one or more embodiments,biomolecular components may include a Left-Handed molecule such as, forexample, an amino acid. In at least one embodiment, the apparatus mayinclude a structure that may be used for promoting the flow of energy(electrons) within a human body so as to improve physical strength of auser, wherein the structure may include a Left-Handed molecule such as,for example, an amino acid.

By way of at least one embodiment, the left-handed material-containingapparatus includes materials specifically pre-selected because suchmaterials may interact with the infrared heat (light) being emitted bythe human body, and thus stimulate the materials inside the patchcausing them to reflect specific wavelengths of light back to the body(phototherapy). In one or more embodiments, a packet of photons, such asone packet, may stimulate a human receptor, such that only very smallamounts of energy are required to cause the photobiomodulation effect.

By way of at least one embodiment, the Left-Handed amino acids that aresuitable for use in at least one embodiment of the invention mayinclude, for example, L-Glutamine, L-Arginine, L-Ornithine, L-Carnitine,L-Taurine, L-Tryptophan, L-Glycine, etc. Preferably, the amino acidsused in at least one embodiment of the invention are orthomolecularamino acids.

In one or more embodiments, the Left-Handed molecule is an amino acidfound in nature. In one or more embodiments, the Left-Handed molecule isan amino acid synthesized by man. In at least one embodiment, aminoacids may include, but not limited to, L-Alanine, L-Arginine,L-Aspargine, L-Aspartic Acid, L-Carnitine, Acetyl-L-Carnitine,L-Carnitine L-Tartrate, L-Carnitine Magnesium Citrate, L-Citrulline,L-Cysteine, L-Cystine, L-GABA, L-Glutamic Acid, L-Glutamine, GlutathionePeroxidase, L-Glycine, L-Histidine, Hydroxyglutamic Acid,Hydroxyproline, L-Isoleucine, L-Leucine, Norleucine, L-Lysine,L-Methionine, L-Ornithine, L-Valine, L-Phenylalanine, L-Proline,L-Serine, L-Taurine, L-Threonine, L-Tryptophan, L-Tyrosine, other formsof Carnitine, etc. In at least one embodiment, the amino acids may begrouped with one or more of the above amino acids. In some embodiments,the Left-Handed molecules may include a synthetic L-sugar (L-glucose) orother synthetic levo-rotatory molecule known to one skilled in the art.

According to at least one embodiment of the invention, the Left-Handedmolecule may be employed in a variety of ways. In one example, thebiomolecular components including the Left-Handed molecules may be usedin the form of a liquid, with said liquid being sprayed or similarlyapplied to a substrate. In another example, the biomolecular componentsincluding the Left-Handed molecule may be used in the form of a solid,such as a powder, with said powder being mixed with a binder such aslatex rubber, silicone rubber, epoxy, wax or the like, with the powderedamino acid and binder being applied to a substrate.

According to at least one embodiment, the invention may include astructure that includes a plurality of Left-Handed molecules. In one ormore embodiments, more than one kind of Left-Handed molecules may beutilized in a structure. In one example, a structure in whichL-glutamine may be applied to a single substrate, followed by thelayering of a second amino acid such as L-Arginine to a secondsubstrate, with both treated substrates forming part of the completedstructure of at least one embodiment of the invention. In one or moreembodiments, portions of L-Glutamine and L-Arginine may be mixedtogether, and then applied in the form of a liquid or powder to a singlesubstrate. In another example, two or more L amino acids may be appliedto the same substrate.

At least one embodiment of the invention may include one or moreadditives for the Left-Handed molecules. The examples of additives mayinclude, but not limited to Glycerin, d-calcium pantothenate, sorbitol,propylparaben, potassium sorbate, methylparaben, Colloidal Copper and/orCollodial Gold, etc.

One or more embodiments of the invention provide an apparatus includinga sealed enclosure, wherein the sealed enclosure may enclosebiomolecular components (e.g., Left-Handed molecules), for example forproviding phototherapy to the human body, and one or more substrates forthe biomolecular components. The sealed enclosure may be made of amaterial, for example, but not limited to a polyester film sheet (e.g.,manufactured by GBC, a thermal laminating film, etc.), a plastic film(e.g., polyethylene, polypropylene, ABS, plexiglass, Lexan, PVC, etc.),etc. In at least one embodiment, the polyester film sheet and/or theplastic film may be utilized in construction of the apparatus of theinvention. In one or more embodiments the sealed enclosure may be madeof a light polarizing film. In other embodiments the sealed enclosuremay be made of a linear low-density film.

According to at least one embodiment of the invention, the sealedenclosure may not react (i.e., chemically, etc.) with biomolecularcomponents (e.g., Left-Handed molecules) of the invention. In one ormore embodiments, the sealed enclosure may be capable of being sealed toa predefined fashion to keep the Left-Handed molecules in a liquidstate. In one or more embodiments, the sealed enclosure may be capableof being sealed in a predefined fashion to protect the Left-Handedmolecules from ambient environmental conditions.

By way of at least one embodiment, examples of methods of sealingplastic films may include, for example, pressure sensitive or thermallysensitive adhesives, ultrasonic sealing, etc.

According to at least one embodiment, the invention provides anapparatus that includes a container, for example a sealed plasticenclosure that encloses biomolecular components, for example forproviding phototherapy to a human body, and one or more substrates forthe biomolecular components, wherein the apparatus further includes oneor more gem stones (e.g., Jade, powdered jade, etc.).

In one or more embodiments, Jade may be used for decorative purposes,and for the practice of the invention. Jade (or other gem stones) may beincorporated into the invention in either gem stone form, or in powderedform. If Jade is incorporated in stone form, then the apparatus of atleast one embodiment of the invention may be embodied as decorativeitems such as jewelry, etc. If Jade is incorporated in powdered form,then the Jade powder may be added to the Left-Handed molecules. The Jademay also be added in other parts of the devices of the invention so asto make the apparatus practical for use.

According to one or more embodiments, the invention provides one or morephysical structural settings for holding one or more components ofapparatus 100. In one or more embodiments, that the one or more physicalstructural settings may hold biomolecular components, for example forproviding phototherapy to the human body, one or more substrates for thebiomolecular components, and one or more gem stones (e.g., Jade,powdered jade, etc.).

According to at least one embodiment, apparatus 100 may be in one ormore of a plurality of wearable objects, for example, but not limited todermal patches, bracelets, pendants, support pads, shirts, socks, footinserts, etc.

According to at least one embodiment, the invention may include a patchhaving an adhesive (e.g., medical grade adhesive). In one or moreembodiments, the invention may include a single patch. In one or moreembodiments, the invention may include a plurality of patches. In oneembodiment, the patch may be constructed in layers made of plastic filmor light polarizing film, polyester fabric as a substrate, Water,L-Carnitine, Glycerin, d-calcium pantothenate, sorbitol, propylparaben,potassium sorbate, and methylparaben. In another embodiment, the patchmay be constructed in layers made of a plastic film or a lightpolarizing film as an enclosure, a polyester fabric as a substrate.

By way of one or more embodiments, apparatus 100 of the presentinvention may be embodied as jewelry items, then the apparatus may bemounted in virtually any jewelry setting that is already commerciallyavailable, provided that the setting does not interfere in any way withthe operation of apparatus 100 of the present invention. In at least oneembodiment, apparatus 100 of the invention may be embodied as a band aidor as a patch (transdermal or non-transdermal), such that a settingwould not be needed. In at least one embodiment, apparatus 100 of theinvention may be completely sealed, thereby the Left-Handed moleculesmay not make direct contact with a user of apparatus 100. In addition,in at least one embodiment, the Left-Handed molecules may not enter intobody of the user.

In one or more embodiments, apparatus 100 of the invention havingLeft-Handed molecules may be manufactured with the followingspecifications:

One or more embodiments of the invention provide a method for placingapparatus 100 on a predetermined location of a human body or into ahuman body, wherein apparatus 100 produces a beneficial effect whenplaced on the human body or into the human body, wherein apparatus 100at least provides phototherapy to the human body for producing thebeneficial effect. The apparatus 100 may include, for example, patch,bracelet, necklace, anklet, etc.

One or more embodiments of the invention provide methods for placingapparatus 100 into proximity of a human body. In one example, apparatus100 may be attached to pendants and allowed to be placed into proximityof the human body. In another example, apparatus 100 may be embodied in“Band Aid” style or “Patch” style, with a medical grade adhesive beingapplied to the device to make it suitable for use with human beings.

In at least one embodiment, apparatus 100 (e.g., dermal patch) havingLeft-Handed molecules may be placed at an electrically POSITIVE point onthe body. Positive and Negative points on the body have been metered andthe locations thereof are known.

Furthermore, in one or more embodiments, apparatus 100 (e.g., dermalpatch) may be placed at known acupuncture points. For example, in one ormore embodiments, apparatus 100 having Left-Handed molecules (e.g.,POSITIVE dermal patch) may be placed at a YANG (positive) point.

According to at least one embodiment of the invention illustrated inFIG. 2A, apparatus 100 may cause a beneficial effect (e.g., improvementin strength/stamina, relief from a pain, etc.), for example by providingphototherapy to a human body, and for example in some embodiments as aresult of elevating copper peptide, including activation of stem cells,improvements in energy, elevation of antioxidants, reduction ininflammation, management of pain, improvements in stamina, elevation ofcollagen production, improved wound healing and may include a singlelayer fabric substrate 110 for retaining biomolecular components.

FIG. 2B illustrates a sealed single layer fabric substrate that retainthe biomolecular components.

According to at least one embodiment of the invention illustrated inFIG. 3A, apparatus 100 that causes beneficial effect (e.g., improvementin strength/stamina, relief from a pain, etc.), for example, byproviding phototherapy to a human body, and may include two layers offabric substrate 120 for retaining biomolecular components including.Apparatus 100, as illustrated, may be fabricated in accordance with theprinciples as described here in the preceding disclosure.

FIG. 3B illustrates a sealed multi-layer fabric substrate that retainthe biomolecular components, according to one or more embodiments of theinvention.

According to at least one embodiment of the invention illustrated inFIG. 4, a patch 400 may include apparatus 100 for causing a beneficialeffect (e.g., improvement in strength/stamina, relief from a pain etc.)for a human body, for example by providing phototherapy to a human body.In one or more embodiments, one or more portions of patch 400 mayinclude medical grade adhesive for enabling attachment of patch 400 tohuman skin surface.

According to at least one embodiment of the invention illustrated inFIG. 5, a bracelet 500 may include apparatus 100 for causing abeneficial effect (e.g., improvement in strength/stamina, relief from apain, etc.) for a human body, for example by providing phototherapy to ahuman body. In one or more embodiments, bracelet 500 may also include agem stone (not shown in FIG. 5).

According to at least one embodiment of the invention illustrated inFIG. 6, a ring 600 may include apparatus 100 for causing a beneficialeffect (e.g., improvement in strength/stamina, relief from a pain, etc.)for a human body, for example by providing phototherapy to a human body.In one or more embodiments, ring 600 may also include a gem stone 610.

According to at least one embodiment of the invention illustrated inFIG. 7, a watch 700 may include apparatus 100 for causing a beneficialeffect (e.g., improvement in strength/stamina, relief from a pain, etc.)for a human body, for example by providing phototherapy human body. Byway of one or more embodiments, the system may include a phototherapydevice system. In at least one embodiment, the system is applied to thesubject's body to provide a beneficial effect for the subject selectedfrom a group consisting of activation of stem cells, an improvement inenergy, an elevation of antioxidants, a reduction in inflammation, anelevation of collagen production, an improvement in wound healing, anincrease in strength, an increase in stamina, a relief from pain and animprovement in strength endurance.

FIG. 8A illustrates a system that includes a first layer that mayinclude one or more of a transdermal patch and a non-transdermal patch,and a second layer with one or more of at least one Left-Handedmaterial-containing apparatus coupled on top of the first layer,according to one or more embodiments of the invention.

As shown in FIG. 8A, at least one embodiment of the invention includes asystem 800 that includes a first layer with a patch 802. In at least oneembodiment, patch 802 may be one or more of a transdermal patch and anon-transdermal patch. In one or more embodiments, the patch 802consists essentially of copper peptide GHK-Cu, such that the patch 802may deliver the copper peptide GHK-Cu into the subject's body 804. In atleast one embodiment of the invention, the system 800 includes a secondlayer 100, such as the apparatus 100 that causes a beneficial effect,for example by providing phototherapy to a human body, illustrated inFIGS. 2A, 2B, 3A, 3B, 4, 5, 6 and 7.

In one or more embodiments of the invention, the second layer 100 iscoupled to the first layer 802, wherein the second layer 100 includesthe at least one Left-Handed material-containing apparatus applied tothe subject's body 804. In one or more embodiments, the second layer mayinclude a plurality of Left-Handed material-containing apparatusessimultaneously applied to the subject's body. In at least oneembodiment, the apparatus and layers thereof may include one or more oforganic and non-organic molecules. In one or more embodiments, the atleast one Left-Handed material-containing apparatus comprises at leastone Left-Handed molecule comprising at least one Left-Handed organicmolecule or at least one Left-Handed non-organic molecule or both atleast one Left-Handed organic molecule and at least one Left-Handednon-organic molecule. By way of at least one embodiment of theinvention, the at least one Left-Handed material-containing apparatusreflects or emits specific wavelengths of light that elevate levels ofthe copper peptide GHK-Cu in the subject's body. In one or moreembodiments, the elevation of levels of the copper peptide GHK-Cuactivates stem cells in the subject's body. For example, by way of atleast one embodiment, the copper peptide may act as a signaling model toincrease proliferation of stem cells. As such, by way of one or moreembodiments, the decline of copper peptide in the subject's body, forexample due to aging, may be improved by elevating or increasing thelevels of the copper peptide using the phototherapy apparatus.

By way of one or more embodiments, the non-transdermal patch may includetwo phototherapy layers as a first phototherapy layer and a secondphototherapy layer. In at least one embodiment, the first phototherapylayer and the second phototherapy layer are layered and coupled on topof each other, such that one layer of the two phototherapy layers islayered and coupled on top of a second layer of the two phototherapylayers. In one or more embodiments, the first phototherapy layer and thesecond phototherapy layer are layered and coupled as concentric rings.In at least one embodiment, via the two phototherapy layers, thenon-transdermal patch reflects different wavelengths of light from eachlayer of the first phototherapy layer and the second phototherapy layer,therefore producing additional beneficial biological effects.

According to one or more embodiments, the phototherapy apparatus maydeliver ingredients to the subject's body that compliment the functionof GHK-Cu, via one or more patches or layers. In at least oneembodiment, the ingredients may include minerals such as copper, zinc,selenium, magnesium and sulphur, wherein such ingredients support woundhealing and thus provide an advantage to the subject's body.

By way of at least one embodiment, as shown in FIG. 8A, the second layer100 is coupled on top of the first layer 802 that includes the patch802.

FIG. 8B illustrates the system 800 that includes the first layer 802with a patch, and the second layer 100 with one or more of at least oneLeft-Handed material-containing apparatus directly coupled to the firstlayer 802 side by side, according to one or more embodiments of theinvention. In at least one embodiment of the invention, the patch mayinclude one or more of a transdermal patch and a non-transdermal patch.For example, some ingredients that are beneficial as non-transdermalembodiments may be configured to encapsulate the ingredients so thatthey do not enter the skin, while other transdermal ingredients may beheld is portions of the device that allow those ingredients to enter theskin. As shown in FIG. 8B, first layer 802 may be implemented with anon-transdermal ingredient that is not configured to enter the skin,while second layer 100 is implemented with a transdermal ingredient thatis configured to enter the skin, or visa versa wherein first layer 802has a transdermal ingredient and is configured to allow that ingredientto enter the skin while second layer 100 has the non-transdermalingredient. Any other embodiment of the invention may also containtransdermal portions depending on the desired application.

FIG. 8C illustrates the system 800 that includes the first layer 802with a patch, and the second layer 100 with one or more of at least oneLeft-Handed material-containing apparatus indirectly coupled to thefirst layer 802 side by side, according to one or more embodiments ofthe invention. In at least one embodiment of the invention, the patchmay include one or more of a transdermal patch and a non-transdermalpatch.

FIG. 8D illustrates the system 800 that includes the first layer 802with a patch, and the second layer 100 with one or more of at least oneLeft-Handed material-containing apparatus layered as concentric rings,according to one or more embodiments of the invention. In at least oneembodiment of the invention, the patch may include one or more of atransdermal patch and a non-transdermal patch. In at least oneembodiment of the invention, the placement of the first layer 802 andthe second layer 100 as concentric rings may be switched such that thefirst layer may fit inside the second layer or vice versa, and such thatthe first layer and the second layer include a common center with anequal distance apart all the way around.

In one or more embodiments of the invention, as shown in FIG. 8C, thefirst layer 802 is coupled to the second layer 100 side by side, whereinthe first layer 802 is separated from the second layer 100, such thatthe first layer 802 attaches to a first portion of the subject's body804 and the second layer 100 attaches to a second portion of thesubject's body 804.

FIG. 9A illustrates an example of a patch including the system thatcauses a beneficial effect within a human body, according to at leastone embodiment of the invention.

According to at least one embodiment of the invention, FIG. 9A shows thepatch 400, as illustrated in FIG. 4 and as discussed above, that mayinclude system 800, to cause a beneficial effect (e.g., improvement instrength/stamina, relief from a pain etc.) for a human body, for exampleby providing phototherapy to a human body, such as the subject's body804.

FIG. 9B illustrates an example of a bracelet including a system thatcauses a beneficial effect within a human body, according to at leastone embodiment of the invention.

According to at least one embodiment of the invention, FIG. 9B shows thebracelet 500, as illustrated in FIG. 5 and as discussed above, that mayinclude system 800, to cause a beneficial effect (e.g., improvement instrength/stamina, relief from a pain, etc.) for a human body, forexample by providing phototherapy to a human body, such as the subject'sbody 804.

FIG. 9C illustrates an example of a ring including a system that causesa beneficial effect within a human body, according to at least oneembodiment of the invention.

According to at least one embodiment of the invention, FIG. 9C shows thering 600, as illustrated in FIG. 6 and as discussed above, that mayinclude system 800, to cause a beneficial effect (e.g., improvement instrength/stamina, relief from a pain, etc.) for a human body, forexample by providing phototherapy to a human body, such as the subject'sbody 804.

FIG. 9D illustrates an example of a watch including a system that causesa beneficial effect within a human body, according to at least oneembodiment of the invention.

According to at least one embodiment of the invention, FIG. 9D shows thewatch 700, as illustrated in FIG. 7 and as discussed above, that mayinclude system 800, to cause a beneficial effect (e.g., improvement instrength/stamina, relief from a pain, etc.) for a human body, forexample by providing phototherapy to a human body, such as the subject'sbody 804.

According to at least one embodiment of the invention, the first layer802 may deliver chemicals and nutrients to the subject's body 804, andthe second layer 100 may not deliver such chemicals and nutrients to thesubject's body 804, for example when applied simultaneously.

FIG. 10A illustrates a patch, such as the non-transdermal patch, with atleast one ball or bead located underneath the patch at an outer surfaceof the patch, according to one or more embodiments of the invention.FIG. 10B illustrates a patch, such as the non-transdermal patch, with atleast one ball or bead located between layers of the patch, according toone or more embodiments of the invention. As shown in FIG. 10A and FIG.10B, the patch, such as the non-transdermal patch, may include at leastone ball or bead 1055. In at least one embodiment, the at least one ballor bead 1055 may be or may include plastic. In one or more embodiments,the at least one ball or bead 1055 may be located at the bottom of thenon-transdermal patch as shown in FIG. 10A, such as underneath thenon-transdermal patch at an outer surface of the non-transdermal patch.For example, in one or more embodiments, the at least one ball or bead1055 may be located at an outer surface of first layer 802 or secondlayer 100. In at least one embodiment of the invention, the at least oneball or bead 1055 may be located underneath the non-transdermal patch,wherein the at least one ball or bead directly or indirectly contactsthe user's skin, such as at user's body 804. In one or more embodiments,the at least one ball or bead 1055 may be located between layers of thenon-transdermal patch, such as for example between the first layer 802and the second layer 100 of the non-transdermal patch. By way of atleast one embodiment, the at least one ball or bead 1055 may stimulatethe user's skin with mild pressure. In one or more embodiments of theinvention, each of the at least one ball or bead may include a diameterof 0.218 inches, 0.187 inches, 0.156 inches or 0.182 inches. Accordingto one or more embodiments of the invention, the ball or bead 1055 maystimulate specific points on the user's skin to provide additionalbeneficial biological effects, such as to mobilize stem cells of theuser.

By way of one or more embodiments, the phototherapy apparatus maystimulate the skin with specific wavelengths of light to elevate thecopper peptide GHK-Cu, such that the copper peptide GHK-Cu mayeffectively stimulate the natural healing process in the subject's body.See “Experimental Study of LiveWave, Inc. X-39 patches”, Summary andreport, The Centre for Biofeld Sciences, Integrated Health, 23 Nov.2018; incorporated herein by references in its entirety.

A pilot study was conducted with forty experimental and five controlvoluntary subjects who were studied before and after wearing the patchfor a period of six weeks, using cutting edge non-invasive screeningtechnologies such as biofield imaging, electro photonic imaging andelectro-interstitial screening. Such devices were used to extract abroad spectrum of data ranging from physical, energetic and emotionalaspects of the subject's body non-invasively and efficiently.Statistical analysis of data revealed a highly significant increase(p<0.0001) in overall energy of subjects' biofield and significantimprovement (p<0.05) in the symmetrical distribution of energy betweenthe organs of the subjects. Also, a significant improvement (p<0.05) invital energy after using the patches for 6 weeks showed positive changesin the biofield of the subjects.

Forty-five subjects aged between 40 to 65 years were randomly selectedto take part in the study of the efficacy of the patch, out of whichforty subjects were in the experimental group and five subjects servedas control group.

The data collection was done in three phases starting with the baselineon the day before the subject start wearing the patches, seconds set ofscans were taken after 3 weeks and the final scans were done after 6weeks from the baseline scan date. The patches were placed at the baseof the back of the neck where C7 vertebrae protrude. The subjects wereinstructed to wear a new patch every day for 12 hours during the daytimefor 6 weeks.

The pilot study demonstrates a statistically significant improvement inthe subjects biofield from using the patch. The statistical analysisrevealed a highly significant improvement (p<0.0001) in overall energyof the person and significant improvement (p<0.05) in the symmetricaldistribution of energy over different organs. From the above, it isconcluded wherein the patch is effective in elevating the overallenergetic vitality of the biofield and the body and also boosting theself-healing mechanisms.

According to at least one embodiment of the invention, thenon-transdermal patch is sealed such that none of the substances in thepatch actually penetrate the skin. In one or more embodiments, thisallows for consistent patch promotion of the light flow throughout thetime the patch is worn. The patch, according to at least one embodiment,stimulates the copper peptide GHK-Cu. By way of one or more embodiments,the patch may be placed on the back, such as at GV14, Du-14 or Dao, at ameeting point of the governing vessel with all of the Yang meridians. Inat least one embodiment, the patch may be placed at a point on the lowerabdomen, at CV-6, Ren 6, or Qi Hai.

See “Metabolic Implications of the LiveWave X39 Patch”, to Connor etal., incorporated herein by reference in its entirety.

This study explores the metabolic implications and physiologic resultsof wearing the patch over the period of one week. Measures were taken atbaseline, 24 hours and at 7 days of wearing the patch. A sample ofconvenience of 15 subjects made up of both men and women aged 40-65 wereselected to participate in this study. In this study, the initialbaseline readings were taken, and then the patch was applied. Theparticipant will be asked to wear the patch 12 hours each day. Theparticipant removed the patch at night and a fresh patch was appliedeach morning prior to 8 am. The patch was worn for a minimum of 1 hourbefore the additional data measures were taken. Patches were worn for atotal of 7 days. Data taking with the patch applied was done on day one,day two and day seven. This study focused on the metabolic impact ofpatch usage, with half the participants using the CV6 point and halfusing the GV14 point.

Amino acids and neurotransmitters play a critical role in the health andwellbeing of individuals. If an individual's amino acid andneurotransmitter production is broken, the individual cannot maintainbody health for long. The number of statistically significant changesdemonstrated in this study shows the powerful impact, which may becreated by the use of phototherapy products, and the clear positivechanges produced by the application of the specific non-transdermalpatch. Key findings are Glutamate and Histamine as they show a distinctanti-inflammatory trend produced by the patch.

Of note, importantly, the amino acids Glycine and Glutamate, which areused for example in the process to form Glutathione in atranssulfuration pathway, both showed a drop off at a level ofsignificance, shown in Table 1 below.

TABLE 1 Glu Day 1 to Day 2 −2.00 6.71 0.2674 Glu Day 2 to Day 7 −3.826.73 0.0453 Glu Day 1 to Day 7 −5.82 10.37 0.0475 Gly Day 1 to Day 2−72.54 117.73 0.0317 Gly Day 2 to Day 7 34.67 107.20 0.2308 Gly Day 1 toDay 7 −37.87 83.70 0.1016

For example, Glutahione is part of the body system that supportsreduction of inflammation pathways in a unique aspect. For example, itspecifically acts from the liver to detoxify the blood. As such, forexample, it clears heavy metals from the body rather than acting as ananti-inflammatory agent directly. A decrease in the materials thatproduce the glutathione as the result of patch usage means that moreglutathione is being made. For example, this results in higheravailability of the glutathione in the blood and allows the body toclear more damaging material faster.

FIG. 11 illustrates an increase in production of Glutathione as a resultof using the patch, providing an improved anti-inflammatory response,via a decrease in the materials that produce the Glutathione, accordingto one or more embodiments of the invention. By way of one or moreembodiments, Glutamate and Glycine both drop to produce Glutathione. Inat least one embodiment, Glutathione is a critical part of theanti-inflammatory pathway. For example, in at least one embodiment ofthe invention, Glycine combines with Glutamate to produce Glutathionethrough the transsulfuration pathway. In one or more embodiments of theinvention, as shown in Table 1 above, between day one and day two,Glycine drops at a level of significance and then starting day two theGlutamate drops at a level of significance. As such, for example,between day one and day seven, Glutathione is produced at a higher leveland thus produces an improved anti-inflammatory response, reducinginflammation, shown in FIG. 11.

For example, fifteen subjects were tested, and as shown in Table 2below, the sample obtained from day 7 shows seven of the fifteensubjects with levels of Glutathione increasing.

TABLE 2 Subject Glutathione Levels  1 Day 1 to Day 7 6.20 6.00 4.21  2Day 1 to Day 7 0.92 0.48 0.61  3 Day 1 to Day 7 0.78 1.39 4.19  4 Day 1to Day 7 1.52 3.74 6.41  5 Day 1 to Day 7 1.16 1.30 2.78  6 Day 1 to Day7 1.75 2.15 1.45  7 Day 1 to Day 7 0.17 0.77 0.16  8 Day 1 to Day 7 1.490.58 1.88  9 Day 1 to Day 7 0.76 0.70 2.42 10 Day 1 to Day 7 0.68 0.412.26 11 Day 1 to Day 7 0.64 1.44 0.69 12 Day 1 to Day 7 0.99 1.43 1.1113 Day 1 to Day 7 1.21 1.49 0.98 14 Day 1 to Day 7 0.94 0.80 1.01 15 Day1 to Day 7 0.97 0.99 1.15

The study also included metabolic testing and physiological testing.Metabolic testing consisted of one 10 am urine taken at baseline/dayone, day two and day seven. Saliva testing consisted of a six swabstaken in one day at baseline/day one, day two and seven. All studyparticipants had the following physiological testing done at base line,24 hours and 7 days: Six minute recordings of EKG, pulse, respiration,heart rate variability (HRV), temp, blood volume pulse, galvanic skinresponse, and 2 EMG (muscle) leads (one on each shoulder area). Atbaseline testing, participants were checked for any allergic reactionsto the adhesive patches. Fresh adhesive patches were used for eachperson tested. Data from questionnaires were collected on standardanswer sheets and scored. All questionnaires parameters were summarizedin terms of means and standard deviation, stratified by assessment timepoint. Changes between assessment time points were evaluated using apaired t-test or nonparametric Wilcoxon Signed Rank test. All physiologyparameters were summarized in terms of means and standard deviation,stratified and across the 6 study epochs. Changes from pre-to post patchadministration were evaluated using a paired t-test. Normal probabilityplots were examined to verify the distribution assumptions. All reportedP-values are two-sided and P<0.05 was used to define statisticalsignificance. All metabolic parameters were summarized in terms of meansand standard deviation, stratified by assessment time point. Changesfrom day 1 (pre-patch) to day 2, day 2 to day 7, and day 1 to day 7 wereevaluated using a paired t-test or nonparametric Wilcoxon Signed Ranktest. Cortisol levels were obtained at 8 am, 12 pm, 4 pm, 8 pm and 12am. DHEAS levels were collected at 8 am, Bpm and 12 am. The area underthe curve (AUC) for Cortisol and DHEAS levels over the data collectionperiods was calculated using the trapezoid rule. AUC levels weresummarized in terms of means and standard deviations, stratified byassessment time point. Changes between assessment time points wereevaluated using a paired t-test or Wilcoxon signed rank test.

The study included five men and 10 women with a mean age of 61.9±9.3years. The results of the testing is summarized with tables below:

TABLE 3 Demographics (N = 15): N (%) Gender Female 10 (67%) Male  5(33%) Age (yrs), means ± SD 61.9 ± 9.3

As shown from Table 3 above, the experiment included five men and 10women with a mean age of 61.9±9.3 years.

TABLE 4 Changes in Arizona Integrative Outcome Scale, Visual AnalogueScale (AIOS-VAS) instrument scores from Consent to 1.2, Consent to day2, and Consent to day 7 assessments: Mean Change SD p-value Change from1.1 to 2 7.6 15.3 0.0877 Change from 1.1 to 7 15.3 20.6 0.0151

For example, the AIOS-VAS looks at the overall wellness of anindividual. As shown above, for example, there was a clear shiftestablished by the second day of testing, which increased tosignificance by day 7 showing clear overall improvement in the feelingsof vitality and wellness.

TABLE 5 Changes in WAISIII instrument scores from day 1 to day 7:Outcome Mean Change SD p-value Change from Day 1 to Day 7 # Short 1.12.4 0.0872 # Mid 0.8 2.9 0.3008 # Long 1.1 3.2 0.2170

For example, the WAIS III is an intelligence test that includes astandard memory test. For example, memory is a common issue for peopleabove age 45. As shown above, for example, there was a clear improvementin short-term memory by day 7. For example, it is likely that this wouldget more significant with a larger group of people and a longerintervention period. As shown above, for example, there was animprovement in both mid and long-term memory as well.

TABLE 6 Changes in modified Pittsburg Sleep Quality Index (PSQI)instrument scores from day 1 to day 2 and from day 1 to day 7: MeanChange SD p-value Change from Day 1 to Day 2 −1.0 1.3 0.0676 Change fromDay 1 to Day 7 −3.0 2.9 0.0522

The PSQI was used to look at sleep, which for example is also a commonissue once past the age of 45. As shown above, the questionnaire showedan immediate strong shift the first night, and a significant shift byday 7. For example, this is particularly important as sleep stronglyaffects the subject's health and wellbeing.

TABLE 7 Change from day 1 (pre-patch) to day 2, day 2 to day 7, and day1 (pre-patch) to day 7: Mean Marker Change Change SD p-value Alanine Day1 to Day 2 −20.17 36.89 0.0526 Cystine Day 2 to Day 7 −16.07 23.860.0206 Epinephrine Day 1 to Day 2 −2.09 3.08 0.0197 Epinephrine Day 2 toDay 7 1.59 2.94 0.0552 GABA Day 1 to Day 7 −0.73 1.50 0.0818 GlutathioneDay 2 to Day 7 −3.82 6.73 0.0453 Glutathione Day 1 to Day 7 −5.82 10.370.0475 Glycine Day 1 to Day 2 −72.54 117.73 0.0317 HCys2 Day 1 to Day 20.35 0.55 0.0296 Histamine Day 1 to Day 2 −46.32 75.35 0.0320 HistamineDay 1 to Day 7 −46.64 49.35 0.0026 Histamine (free) Day 1 to Day 2 −9.2420.20 0.0981 Hydroxylysine Day 1 to Day 7 −0.80 1.75 0.0992 Leucine Day1 to Day 2 −4.84 7.84 0.0313 Normetanephrine Day 2 to Day 7 −13.06 23.320.0479 PEA Day 1 to Day 7 −0.59 1.12 0.0589 PhenylethylaminePhenylalanine Day 2 to Day 7 6.33 10.94 0.0418 Tryptophan Day 2 to Day 7−10.81 18.55 0.0406 Alpha- Day 1 to Day 7 −8.90 13.79 0.0256aminobutyric acid Alpha- Day 2 to Day 7 −5.29 7.79 0.0198 aminobutyricacid

For example, amino acids and neurotransmitters play a critical role inthe health and wellbeing of individuals. For example, if an individual'samino acid and neurotransmitter production is broken, the individual maynot maintain body health for long. For example, the number ofstatistically significant changes demonstrated in this study shows thepowerful impact that may be created by the use of phototherapy productsand the clear positive changes produced by the application of thisspecific non-transdermal patch, by way of one or more embodiments of theinvention. Key findings are Glutamate and Histamine as they show adistinct anti-inflammatory trend produced by the patch.

Of note, importantly, the amino acids Glycine and Glutamate, which areused in the process to form Glutathione in a transsulfuration pathway,both showed a drop off at a level of significance. For example,glutathione is part of the body system that supports reduction ofinflammation pathways in a unique aspect. For example, it specificallyacts from the liver to detoxify the blood, as discussed above. Adecrease in the materials that produce the glutathione as the result ofpatch usage means that more glutathione is being made. This results inhigher availability of the glutathione in the blood and allows the bodyto clear more damaging material faster. This supports the overallreduction in inflammation, which is demonstrated in the data results.

TABLE 8 Change from pre-patch to last-patch (day 7) of High Frequency(HF), a ratio of Low Frequency to High Frequency (LF/HF) of number ofpairs of successive NN (R-R) intervals that differ by more than 50 ms(NN50), proportion of NN50 divided by the total number of NN (R-R)intervals (PNN50), Power, root mean square of the successive differences(RMSSD), and very low frequency (VLF), stratified by Epoch (1-6): MeanSource Outcome Epoch Change SD p-value EKG SDNN 2 −42.89 82.71 0.06430BVP HF 5 −1085.13 2038.55 0.05830 BVP NN50 1 −3.13 5.34 0.03950 BVP NN502 −2.13 4.12 0.06470 BVP NN50 3 −1.73 2.89 0.03580 BVP NN50 5 −2.73 3.030.00360 BVP PNN50 1 −0.05 0.08 0.03820 BVP PNN50 2 −0.03 0.07 0.06880BVP PNN50 3 −0.03 0.04 0.04290 BVP PNN50 5 −0.04 0.04 0.00360 BVP RMSSD5 −21.13 36.49 0.04160 BVP SDNN 5 −19.42 27.08 0.01480 BVP VLF 5 −382.47426.65 0.00370

TABLE 9 Change from pre-patch to last-patch (day 7) of HF, LF/HF NN50,PNN50, Power, RMSSD, and VLF, across all 6 Epochs: Mean p- SourceOutcome Change SD value EKG HF −1115.01 28492.47 0.7113 EKG LF 14424.43104293.22 0.1929 EKG LF/HF 0.28 1.31 0.0487 BVP HF −786.72 3852.920.0559 BVP LF 205.48 4414.61 0.6599 BVP LF/HF −0.08 5.93 0.9004 BVP NN50−1.96 3.80 <.0001 BVP PNN50 −0.03 0.06 <.0001 BVP RMSSD −21.78 76.480.0083 BVP SDNN −18.60 63.27 0.0065

TABLE 10 Change from pre-patch to last-patch (day 7) of blood volumepulse-heart rate (BVP-HR), electromyography (EMG), Skin-Condition,Temperature and Respiratory Rate for Average, Mode, and Area, stratifiedby Epoch (1-6): Mean p- Source Outcome Epoch Change SD value BVPHRAverage 2 4.51 7.83 0.0426 BVPHRMaxMin Average 5 −2.23 3.13 0.0153BVPHRMaxMin Mode 1 −1.18 2.17 0.0533 BVPHRMaxMin Mode 2 −0.73 1.570.0917 EKGHRMaxMin Mode 6 −33.34 67.42 0.0871 RespRate Mode 1 1.92 4.030.0868

TABLE 11 Change from pre-patch to last-patch (day 7) of BVP-HR, EMG,Skin- Condition, Temperature and Respiratory Rate for Average, Mode, andArea, across all 6 Epochs: Mean p- Source Outcome Change SD value BVPHRAverage 2.54 8.31 0.0047 BVPHR Mode 2.31 9.60 0.0249 BVPHRMaxMin Average−1.67 5.50 0.0049 EMG Average −39.44 124.62 0.0035 EMG Mode −38.45128.72 0.0057 EMG Area −2366.63 7477.30 0.0035

As shown above, reduction in blood pressure and improved musclerelaxation are consistent changes that are present in the physiologydata. For example, the study importantly shows greater flexibility inHRV in the over age 60 population.

As shown above, by way of one or more embodiments, the patch providesimprovement in blood pressure and shows the impact of the metabolicchanges shown in amino acid production. Key findings are Glutathione andHistamine results as they show a distinct anti-inflammatory trendproduced by the patch, according to at least one embodiment. Forexample, such a result is further confirmed when looking at Glycine andGlutamate in combination, wherein they are used in the metabolicprocesses to form Glutathione through the transsulfuration pathway.Since both showed a drop off at a level of significance, thisimportantly shows that they are being used for the purpose of theproduction of Glutathione, since Glutathione is part of the body systemthat supports reduction of inflammation pathways in a unique aspect todetoxify the blood.

As shown above, by way of one or more embodiments, the patch showedwherein flexibility in the gut systems may be able to be restored. Forexample, as one ages there is often less flexibility in all the bodysystems. By way of at least one embodiment, the patch triggers change inthe gut.

As shown above, by way of one or more embodiments, the patch showedwherein changes were in most of the types of amino acids and not limitedto a single type of amino acid. For example, the changes includedessential, non-essential, branched chain essential, aromatic andnon-proteinogenic amino acids instead of a single amino acid or area ofamino acid production.

As shown above, by way of one or more embodiments, the patch showedsignificant improvement (0.08) in short term memory within a week.

As shown above, for example, by way of at least one embodiment, thepatch provides improvement in blood pressure, significant metabolicimprovement, 17 statistically significant amino acid changes over the 7days, significant improvement in anti-inflammatory response, improvementin sleep levels, reduction in blood pressure, improvement in memory,such as in short term memory, and improvement in reported feelings ofvitality.

EXAMPLES

With respect to the non-transdermal patch, the following formulas may beutilized to create embodiments of the invention.

Example 1

TABLE 12 At least one embodiment of the invention includes: MaterialAmount Distilled Water  0.4 gallons Vegetable Glycerin  4.5 poundsL-Lysine   4 grams GHK-Cu  140 mg Zinc Gluconate   1 gram ColloidalCopper 20 ppm   50 ml

According to at least one embodiment of the invention, a clean and drycontainer is placed on a scale, having a capacity of at least 1 gallon.Glycerin is dispensed into the container and measured to be 4.5 pounds.Distilled water is then added to the container in the amount of 0.4Gallons. The contents are then mixed for 1 minute until by visualinspection a uniform mixture has been obtained. Optionally, a magneticmixer may be used, and the mixer is left on for the full duration of theprocessing. After the glycerin and water have mixed together, theL-Lysine is measured on a scale to 4 grams and then added; this isallowed to mix for 1 minute. GHK-Cu is then added to the container inthe amount of 140 mg, and this is allowed to mix for 1 minute. ZincGluconate is measured to the amount of 1 gram, and this is allowed tomix for 1 minute. Colloidal Copper is then added in the amount of 50 mland mixed for 1 minute. The solution is then mixed for an additional 10minutes or until a uniform solution has been formed, with no solids inthe solution. This will make about 1 gallon of solution. This containeris then sealed and then transferred to a cold storage unit, operating ata temperature above freezing, for a period of at least 24 hours. Thesolution may then be dispensed and placed into patches or one or moreother embodiments of the invention.

Example 2

TABLE 13 At least one embodiment of the invention includes: MaterialAmount Distilled Water  0.4 gallons Vegetable Glycerin  4.5 poundsL-Glutamine   4 grams GHK-Cu  140 mg Zinc Gluconate   1 gram ColloidalCopper 20 ppm   50 ml

According to at least one embodiment of the invention, a clean and drycontainer is placed on a scale, having a capacity of at least 1 gallon.Glycerin is dispensed into the container and measured to be 4.5 pounds.Distilled water is then added to the container in the amount of 0.4Gallons. The contents are then mixed for 1 minute until by visualinspection a uniform mixture has been obtained. Optionally, a magneticmixer may be used, and the mixer is left on for the full duration of theprocessing. After the glycerin and water have mixed together, theL-Glutamine is measured on a scale to 4 grams and then added; this isallowed to mix for 1 minute. GHK-Cu is then added to the container inthe amount of 140 mg, and this is allowed to mix for 1 minute. ZincGluconate is measured to the amount of 1 gram, and this is allowed tomix for 1 minute. Colloidal Copper is then added in the amount of 50 mland mixed for 1 minute. The solution is then mixed for an additional 10minutes or until a uniform solution has been formed, with no solids inthe solution. This will make about 1 gallon of solution. This containeris then sealed and then transferred to a cold storage unit, operating ata temperature above freezing, for a period of at least 24 hours. Thesolution may then be dispensed and placed into patches or otherembodiments of the invention.

Example 3

TABLE 14 At least one embodiment of the invention includes: MaterialAmount Distilled Water  0.4 gallons Vegetable Glycerin  4.5 poundsL-Arginine   4 grams GHK-Cu  140 mg Zinc Gluconate   1 gram ColloidalCopper 20 ppm   50 ml

According to at least one embodiment of the invention, a clean and drycontainer is placed on a scale, having a capacity of at least 1 gallon.Glycerin is dispensed into the container and measured to be 4.5 pounds.Distilled water is then added to the container in the amount of 0.4Gallons. The contents are then mixed for 1 minute until by visualinspection a uniform mixture has been obtained. Optionally, a magneticmixer may be used, and the mixer is left on for the full duration of theprocessing. After the glycerin and water have mixed together, theL-Arginine is measured on a scale to 4 grams and then added; this isallowed to mix for 1 minute. GHK-Cu is then added to the container inthe amount of 140 mg, and this is allowed to mix for 1 minute. ZincGluconate is measured to the amount of 1 gram, and this is allowed tomix for 1 minute. Colloidal Copper is then added in the amount of 50 mland mixed for 1 minute. The solution is then mixed for an additional 10minutes or until a uniform solution has been formed, with no solids inthe solution. This will make about 1 gallon of solution. This containeris then sealed and then transferred to a cold storage unit, operating ata temperature above freezing, for a period of at least 24 hours. Thesolution may then be dispensed and placed into patches or otherembodiments of the invention.

Example 4

TABLE 15 At least one embodiment of the invention includes: MaterialAmount Distilled Water  0.4 gallons Vegetable Glycerin  4.5 poundsL-Glycine   4 grams GHK-Cu  140 mg Zinc Gluconate   1 gram ColloidalCopper 20 ppm   50 ml

According to at least one embodiment of the invention, a clean and drycontainer is placed on a scale, having a capacity of at least 1 gallon.Glycerin is dispensed into the container and measured to be 4.5 pounds.Distilled water is then added to the container in the amount of 0.4Gallons. The contents are then mixed for 1 minute until by visualinspection a uniform mixture has been obtained. Optionally, a magneticmixer may be used, and the mixer is left on for the full duration of theprocessing. After the glycerin and water have mixed together, theL-Glycine is measured on a scale to 4 grams and then added; this isallowed to mix for 1 minute. GHK-Cu is then added to the container inthe amount of 140 mg, and this is allowed to mix for 1 minute. ZincGluconate is measured to the amount of 1 gram, and this is allowed tomix for 1 minute. Colloidal Copper is then added in the amount of 50 mland mixed for 1 minute. The solution is then mixed for an additional 10minutes or until a uniform solution has been formed, with no solids inthe solution. This will make about 1 gallon of solution. This containeris then sealed and then transferred to a cold storage unit, operating ata temperature above freezing, for a period of at least 24 hours. Thesolution may then be dispensed and placed into patches or otherembodiments of the invention.

Example 5

TABLE 16 At least one embodiment of the invention includes: MaterialAmount Distilled Water 0.4 gallons Vegetable Glycerin 4.5 poundsL-Carnitine 4 grams GHK-Cu 140 mg Zinc Gluconate 1 gram Colloidal Copper20 ppm 50 ml

According to at least one embodiment of the invention, a clean and drycontainer is placed on a scale, having a capacity of at least 1 gallon.Glycerin is dispensed into the container and measured to be 4.5 pounds.Distilled water is then added to the container in the amount of 0.4Gallons. The contents are then mixed for 1 minute until by visualinspection a uniform mixture has been obtained. Optionally, a magneticmixer may be used, and the mixer is left on for the full duration of theprocessing. After the glycerin and water have mixed together, theL-Carnitine is measured on a scale to 4 grams and then added; this isallowed to mix for 1 minute. GHK-Cu is then added to the container inthe amount of 140 mg, and this is allowed to mix for 1 minute. ZincGluconate is measured to the amount of 1 gram, and this is allowed tomix for 1 minute. Colloidal Copper is then added in the amount of 50 mland mixed for 1 minute. The solution is then mixed for an additional 10minutes or until a uniform solution has been formed, with no solids inthe solution. This will make about 1 gallon of solution. This containeris then sealed and then transferred to a cold storage unit, operating ata temperature above freezing, for a period of at least 24 hours. Thesolution may then be dispensed and placed into patches or otherembodiments of the invention.

Example 6

TABLE 17 At least one embodiment of the invention includes: MaterialAmount Distilled Water 0.4 gallons Vegetable Glycerin 4.5 poundsL-Carnitine 4 grams L-Lysine 400 mg GHK-Cu 150 mg Zinc Gluconate 1 gramColloidal Copper 20 ppm 50 ml

According to at least one embodiment of the invention, a clean and drycontainer is placed on a scale, having a capacity of at least 1 gallon.Glycerin is dispensed into the container and measured to be 4.5 pounds.Distilled water is then added to the container in the amount of 0.4Gallons. The contents are then mixed for 1 minute until by visualinspection a uniform mixture has been obtained. Optionally, a magneticmixer may be used, and the mixer is left on for the full duration of theprocessing. After the glycerin and water have mixed together, theL-Carnitine is measured on a scale to 4 grams and then added; this isallowed to mix for 1 minute. L-Lysine is measured to an amount of 400 mgand then added and mixed for 1 minute. GHK-Cu is then added to thecontainer in the amount of 150 mg, and this is allowed to mix for 1minute. Zinc Gluconate is measured to the amount of 1 gram, and this isallowed to mix for 1 minute. Colloidal Copper is then added in theamount of 50 ml and mixed for 1 minute. The solution is then mixed foran additional 10 minutes or until a uniform solution has been formed,with no solids in the solution. This will make about 1 gallon ofsolution. This container is then sealed and then transferred to a coldstorage unit, operating at a temperature above freezing, for a period ofat least 24 hours. The solution may then be dispensed and placed intopatches or other embodiments of the invention.

Example 7

TABLE 18 At least one embodiment of the invention includes: MaterialAmount Distilled Water 0.4 gallons Vegetable Glycerin 4.5 poundsL-Carnitine 4 grams L-Lysine 400 mg GHK-Cu 150 mg Zinc Gluconate 1 gram

According to at least one embodiment of the invention, a clean and drycontainer is placed on a scale, having a capacity of at least 1 gallon.Glycerin is dispensed into the container and measured to be 4.5 pounds.Distilled water is then added to the container in the amount of 0.4Gallons. The contents are then mixed for 1 minute until by visualinspection a uniform mixture has been obtained. Optionally, a magneticmixer may be used, and the mixer is left on for the full duration of theprocessing. After the glycerin and water have mixed together, theL-Carnitine is measured on a scale to 4 grams and then added; this isallowed to mix for 1 minute. L-Lysine is measured to an amount of 400 mgand then added and mixed for 1 minute. GHK-Cu is then added to thecontainer in the amount of 150 mg, and this is allowed to mix for 1minute. Zinc Gluconate is measured to the amount of 1 gram, and this isallowed to mix for 1 minute. The solution is then mixed for anadditional 10 minutes or until a uniform solution has been formed, withno solids in the solution. This will make about 1 gallon of solution.This container is then sealed and then transferred to a cold storageunit, operating at a temperature above freezing, for a period of atleast 24 hours. The solution may then be dispensed and placed intopatches or other embodiments of the invention.

Example 8

TABLE 19 At least one embodiment of the invention includes: MaterialAmount Distilled Water 0.4 gallons Vegetable Glycerin 4.5 poundsL-Carnitine 4 grams L-Lysine 400 mg GHK-Cu 150 mg Zinc Gluconate 1 gramMalic Acid, Citric Acid As needed to adjust pH Potassium Sorbate 1 gram

According to at least one embodiment of the invention, a clean and drycontainer is placed on a scale, having a capacity of at least 1 gallon.Glycerin is dispensed into the container and measured to be 4.5 pounds.Distilled water is then added to the container in the amount of 0.4Gallons. The contents are then mixed for 1 minute until by visualinspection a uniform mixture has been obtained. Optionally, a magneticmixer may be used, and the mixer is left on for the full duration of theprocessing. After the glycerin and water have mixed together, theL-Carnitine is measured on a scale to 4 grams and then added; this isallowed to mix for 1 minute. L-Lysine is measured to an amount of 400 mgand then added and mixed for 1 minute. GHK-Cu is then added to thecontainer in the amount of 150 mg, and this is allowed to mix for 1minute. Zinc Gluconate is measured to the amount of 1 gram, and this isallowed to mix for 1 minute. At this point Malic Acid and Citric Acidmay be introduced to pH adjust and balance the solution as needed. 1gram of Potassium Sorbate is then added and allowed to mix for 5minutes. The solution is then mixed for an additional 10 minutes oruntil a uniform solution has been formed, with no solids in thesolution. This will make about 1 gallon of solution. This container isthen sealed and then transferred to a cold storage unit, operating at atemperature above freezing, for a period of at least 24 hours. Thesolution may then be dispensed and placed into patches or otherembodiments of the invention.

Example 9

TABLE 20 At least one embodiment of the invention includes: MaterialAmount Distilled Water 0.4 gallons Sodium Metasilicate 500 mg VegetableGlycerin 4.5 pounds L-Carnitine 4 grams L-Lysine 400 mg GHK-Cu 150 mgZinc Gluconate 1 gram Malic Acid, Citric Acid As needed to adjust pHPotassium Sorbate 1 gram

According to at least one embodiment of the invention, a clean and drycontainer is placed on a scale, having a capacity of at least 1 gallon.Glycerin is dispensed into the container and measured to be 4.5 pounds.Distilled water is then added to the container in the amount of 0.4Gallons. The contents are then mixed for 1 minute until by visualinspection a uniform mixture has been obtained. Optionally, a magneticmixer may be used, and the mixer is left on for the full duration of theprocessing. After the glycerin and water have mixed together, theL-Carnitine is measured on a scale to 4 grams and then added; this isallowed to mix for 1 minute. Sodium Metasilicate is measured to 500 mgand added to the container and then mixed for 1 minute. L-Lysine ismeasured to an amount of 400 mg and then added and mixed for 1 minute.GHK-Cu is then added to the container in the amount of 150 mg, and thisis allowed to mix for 1 minute. Zinc Gluconate is measured to the amountof 1 gram, and this is allowed to mix for 1 minute. At this point MalicAcid and Citric Acid may be introduced to pH adjust and balance thesolution as needed. 1 gram of Potassium Sorbate is then added andallowed to mix for 5 minutes. The solution is then mixed for anadditional 10 minutes or until a uniform solution has been formed, withno solids in the solution. This will make about 1 gallon of solution.This container is then sealed and then transferred to a cold storageunit, operating at a temperature above freezing, for a period of atleast 24 hours. The solution may then be dispensed and placed intopatches or other embodiments of the invention.

Example 10

TABLE 21 At least one embodiment of the invention includes: MaterialAmount Distilled Water 0.4 gallons Vegetable Glycerin 4.5 poundsL-Carnitine 4 grams L-Lysine 400 mg GHK-Cu 150 mg Zinc Gluconate 1 gramMalic Acid, Citric Acid As needed to adjust pH Potassium Sorbate 1 gram

According to at least one embodiment of the invention, a full spectrumlight is setup so as to be positioned so that the output from the lightgoes thru a diffraction grating, and the now separated light comes intocontact with a vessel containing 1 gallon of distilled water. The wateris treated for a period of 24 hours prior to being used below.

A clean and dry container is placed on a scale, having a capacity of atleast 1 gallon. Glycerin is dispensed into the container and measured tobe 4.5 pounds. Distilled water is then added to the container in theamount of 0.4 Gallons. The contents are then mixed for 1 minute until byvisual inspection a uniform mixture has been obtained. Optionally, amagnetic mixer may be used, and the mixer is left on for the fullduration of the processing. After the glycerin and water have mixedtogether, the L-Carnitine is measured on a scale to 4 grams and thenadded; this is allowed to mix for 1 minute. L-Lysine is measured to anamount of 400 mg and then added and mixed for 1 minute. GHK-Cu is thenadded to the container in the amount of 150 mg, and this is allowed tomix for 1 minute. Zinc Gluconate is measured to the amount of 1 gram,and this is allowed to mix for 1 minute. At this point Malic Acid andCitric Acid may be introduced to pH adjust and balance the solution asneeded. 1 gram of Potassium Sorbate is then added and allowed to mix for5 minutes. The solution is then mixed for an additional 10 minutes oruntil a uniform solution has been formed, with no solids in thesolution. This will make about 1 gallon of solution. This container isthen sealed and then transferred to a cold storage unit, operating at atemperature above freezing, for a period of at least 24 hours. Thesolution may then be dispensed and placed into patches or otherembodiments of the invention.

Example 11

TABLE 22 At least one embodiment of the invention includes: MaterialAmount Distilled Water 0.4 gallons Vegetable Glycerin 4.5 poundsL-Carnitine 4 grams L-Lysine 400 mg GHK-Cu 150 mg Zinc Gluconate 1 gramMalic Acid, Citric Acid As needed to adjust pH Potassium Sorbate 1 gram

A double helix conductor as described in U.S. Pat. No. 8,653,925,entitled “Double Helix Conductor”, to Schmidt, is setup on a fixture andis of such size that a glass vessel containing 1 gallon of water fitsinside the center opening of the double helix conductor. The water isthen treated for a period of 24 hours in accordance with the teachingsof this invention prior to being used in the process below.

According to at least one embodiment of the invention, a clean and drycontainer is placed on a scale, having a capacity of at least 1 gallon.Glycerin is dispensed into the container and measured to be 4.5 pounds.Distilled water is then added to the container in the amount of 0.4Gallons. The contents are then mixed for 1 minute until by visualinspection a uniform mixture has been obtained. Optionally, a magneticmixer may be used, and the mixer is left on for the full duration of theprocessing. After the glycerin and water have mixed together, theL-Carnitine is measured on a scale to 4 grams and then added; this isallowed to mix for 1 minute. L-Lysine is measured to an amount of 400 mgand then added and mixed for 1 minute. GHK-Cu is then added to thecontainer in the amount of 150 mg, and this is allowed to mix for 1minute. Zinc Gluconate is measured to the amount of 1 gram, and this isallowed to mix for 1 minute. At this point Malic Acid and Citric Acidmay be introduced to pH adjust and balance the solution as needed. 1gram of Potassium Sorbate is then added and allowed to mix for 5minutes. The solution is then mixed for an additional 10 minutes oruntil a uniform solution has been formed, with no solids in thesolution. This will make about 1 gallon of solution. This container isthen sealed and then transferred to a cold storage unit, operating at atemperature above freezing, for a period of at least 24 hours. Thesolution may then be dispensed and placed into patches or otherembodiments of the invention.

Example 12

TABLE 23 At least one embodiment of the invention includes: MaterialAmount Distilled Water 0.4 gallons Vegetable Glycerin 4.5 poundsL-Glycine 4 grams L-Lysine 400 mg GHK-Cu 150 mg Zinc Gluconate 1 gramMalic Acid, Citric Acid As needed to adjust pH Potassium Sorbate 1 gram

A double helix conductor as described in U.S. Pat. No. 8,653,925,entitled “Double Helix Conductor”, to Schmidt, is setup on a fixture andis of such size that a glass vessel containing 1 gallon of water fitsinside the center opening of the double helix conductor. The water isthen treated for a period of 24 hours in accordance with the teachingsof this invention prior to being used in the process below.

According to at least one embodiment of the invention, a clean and drycontainer is placed on a scale, having a capacity of at least 1 gallon.Glycerin is dispensed into the container and measured to be 4.5 pounds.Distilled water is then added to the container in the amount of 0.4Gallons. The contents are then mixed for 1 minute until by visualinspection a uniform mixture has been obtained. Optionally, a magneticmixer may be used, and the mixer is left on for the full duration of theprocessing. After the glycerin and water have mixed together, theL-Glycine is measured on a scale to 4 grams and then added; this isallowed to mix for 1 minute. L-Lysine is measured to an amount of 400 mgand then added and mixed for 1 minute. GHK-Cu is then added to thecontainer in the amount of 150 mg, and this is allowed to mix for 1minute. Zinc Gluconate is measured to the amount of 1 gram, and this isallowed to mix for 1 minute. At this point Malic Acid and Citric Acidmay be introduced to pH adjust and balance the solution as needed. 1gram of Potassium Sorbate is then added and allowed to mix for 5minutes. The solution is then mixed for an additional 10 minutes oruntil a uniform solution has been formed, with no solids in thesolution. This will make about 1 gallon of solution. This container isthen sealed and then transferred to a cold storage unit, operating at atemperature above freezing, for a period of at least 24 hours. Thesolution may then be dispensed and placed into patches or otherembodiments of the invention.

Example 13

TABLE 24 At least one embodiment of the invention includes: MaterialAmount Distilled Water 0.4 gallons Vegetable Glycerin 4.5 poundsL-Glycine 4 grams L-Lysine 400 mg GHK-Cu 150 mg Zinc Gluconate 1 gramMalic Acid, Citric Acid As needed to adjust pH Potassium Sorbate 1 gram

A double helix conductor as described in U.S. Pat. No. 8,653,925,entitled “Double Helix Conductor”, to Schmidt, is setup on a fixture andis of such size that a glass vessel containing 1 gallon of water fitsinside the center opening of the double helix conductor. The water isthen treated for a period of 24 hours in accordance with the teachingsof this invention prior to being used in the process below.

According to at least one embodiment of the invention, the containerbelow is setup using a lily impeller or other mixing blade such that thewater-based solution below will vortex as it is mixed.

A clean and dry container is placed on a scale, having a capacity of atleast 1 gallon.

Glycerin is dispensed into the container and measured to be 4.5 pounds.Distilled water is then added to the container in the amount of 0.4Gallons. The contents are then mixed for 1 minute until by visualinspection a uniform mixture has been obtained. Optionally, a magneticmixer may be used, and the mixer is left on for the full duration of theprocessing. After the glycerin and water have mixed together, theL-Glycine is measured on a scale to 4 grams and then added; this isallowed to mix for 1 minute. L-Lysine is measured to an amount of 400 mgand then added and mixed for 1 minute. GHK-Cu is then added to thecontainer in the amount of 150 mg, and this is allowed to mix for 1minute. Zinc Gluconate is measured to the amount of 1 gram, and this isallowed to mix for 1 minute. At this point Malic Acid and Citric Acidmay be introduced to pH adjust and balance the solution as needed. 1gram of Potassium Sorbate is then added and allowed to mix for 5minutes. The solution is then mixed for an additional 10 minutes oruntil a uniform solution has been formed, with no solids in thesolution. This will make about 1 gallon of solution. This container isthen sealed and then transferred to a cold storage unit, operating at atemperature above freezing, for a period of at least 24 hours. Thesolution may then be dispensed and placed into patches or otherembodiments of the invention.

Example 14

TABLE 25 At least one embodiment of the invention includes: MaterialAmount Distilled Water 0.4 gallons Vegetable Glycerin 4.5 poundsL-Carnitine 4 grams L-Lysine 400 mg GHK-Cu 150 mg Zinc Gluconate 1 gramMalic Acid, Citric Acid As needed to adjust pH Potassium Sorbate 1 gram

A double helix conductor as described in U.S. Pat. No. 8,653,925,entitled “Double Helix Conductor”, to Schmidt, is setup on a fixture andis of such size that a glass vessel containing 1 gallon of water fitsinside the center opening of the double helix conductor. The water isthen treated for a period of 24 hours in accordance with the teachingsof this invention prior to being used in the process below.

According to at least one embodiment of the invention, the containerbelow is setup using a lily impeller or other mixing blade such that thewater-based solution below will vortex as it is mixed.

A clean and dry container is placed on a scale, having a capacity of atleast 1 gallon. Glycerin is dispensed into the container and measured tobe 4.5 pounds. Distilled water is then added to the container in theamount of 0.4 Gallons. The contents are then mixed for 1 minute until byvisual inspection a uniform mixture has been obtained. Optionally, amagnetic mixer may be used, and the mixer is left on for the fullduration of the processing. After the glycerin and water have mixedtogether, the L-Carnitine is measured on a scale to 4 grams and thenadded; this is allowed to mix for 1 minute. L-Lysine is measured to anamount of 400 mg and then added and mixed for 1 minute. GHK-Cu is thenadded to the container in the amount of 150 mg, and this is allowed tomix for 1 minute. Zinc Gluconate is measured to the amount of 1 gram,and this is allowed to mix for 1 minute. At this point Malic Acid andCitric Acid may be introduced to pH adjust and balance the solution asneeded. 1 gram of Potassium Sorbate is then added and allowed to mix for5 minutes. The solution is then mixed for an additional 10 minutes oruntil a uniform solution has been formed, with no solids in thesolution. This will make about 1 gallon of solution. This container isthen sealed and then transferred to a cold storage unit, operating at atemperature above freezing, for a period of at least 24 hours. Thesolution may then be dispensed and placed into patches or otherembodiments of the invention.

Example 15

TABLE 26 At least one embodiment of the invention includes: MaterialAmount Distilled Water 0.4 gallons Vegetable Glycerin 4.5 poundsL-Carnitine 4 grams GHK-Cu 150 mg Zinc Gluconate 1 gram Malic Acid,Citric Acid As needed to adjust pH Potassium Sorbate 1 gram

A double helix conductor as described in U.S. Pat. No. 8,653,925,entitled “Double Helix Conductor”, to Schmidt, is setup on a fixture andis of such size that a glass vessel containing 1 gallon of water fitsinside the center opening of the double helix conductor. The water isthen treated for a period of 24 hours in accordance with the teachingsof this invention prior to being used in the process below.

According to at least one embodiment of the invention, the containerbelow is setup using a lily impeller or other mixing blade such that thewater-based solution below will vortex as it is mixed.

A clean and dry container is placed on a scale, having a capacity of atleast 1 gallon. Glycerin is dispensed into the container and measured tobe 4.5 pounds. Distilled water is then added to the container in theamount of 0.4 Gallons. The contents are then mixed for 1 minute until byvisual inspection a uniform mixture has been obtained. Optionally, amagnetic mixer may be used, and the mixer is left on for the fullduration of the processing. After the glycerin and water have mixedtogether, the L-Carnitine is measured on a scale to 4 grams and thenadded; this is allowed to mix for 1 minute. GHK-Cu is then added to thecontainer in the amount of 150 mg, and this is allowed to mix for 1minute. Zinc Gluconate is measured to the amount of 1 gram, and this isallowed to mix for 1 minute. At this point Malic Acid and Citric Acidmay be introduced to pH adjust and balance the solution as needed. 1gram of Potassium Sorbate is then added and allowed to mix for 5minutes. The solution is then mixed for an additional 10 minutes oruntil a uniform solution has been formed, with no solids in thesolution. This will make about 1 gallon of solution. This container isthen sealed and then transferred to a cold storage unit, operating at atemperature above freezing, for a period of at least 24 hours. Thesolution may then be dispensed and placed into patches or otherembodiments of the invention.

Example 16

TABLE 27 At least one embodiment of the invention includes: MaterialAmount Distilled Water 0.4 gallons Vegetable Glycerin 4.5 poundsL-Carnitine 4 grams GHK 150 mg Zinc Gluconate 1 gram Colloidal Copper 20ppm 50 ml Malic Acid, Citric Acid As needed to adjust pH PotassiumSorbate 1 gram

A double helix conductor as described in U.S. Pat. No. 8,653,925,entitled “Double Helix Conductor”, to Schmidt, is setup on a fixture andis of such size that a glass vessel containing 1 gallon of water fitsinside the center opening of the double helix conductor. The water isthen treated for a period of 24 hours in accordance with the teachingsof this invention prior to being used in the process below.

According to at least one embodiment of the invention, the containerbelow is setup using a lily impeller or other mixing blade such that thewater-based solution below will vortex as it is mixed.

A clean and dry container is placed on a scale, having a capacity of atleast 1 gallon. Glycerin is dispensed into the container and measured tobe 4.5 pounds. Distilled water is then added to the container in theamount of 0.4 Gallons. The contents are then mixed for 1 minute until byvisual inspection a uniform mixture has been obtained. Optionally, amagnetic mixer may be used, and the mixer is left on for the fullduration of the processing. After the glycerin and water have mixedtogether, the L-Carnitine is measured on a scale to 4 grams and thenadded; this is allowed to mix for 1 minute. GHK is then added to thecontainer in the amount of 150 mg, and this is allowed to mix for 1minute. Zinc Gluconate is measured to the amount of 1 gram, and this isallowed to mix for 1 minute. Colloidal Copper is measured to 50 ml andthen added to the container and mixed for 1 minute. At this point MalicAcid and Citric Acid may be introduced to pH adjust and balance thesolution as needed. 1 gram of Potassium Sorbate is then added andallowed to mix for 5 minutes. The solution is then mixed for anadditional 10 minutes or until a uniform solution has been formed, withno solids in the solution. This will make about 1 gallon of solution.This container is then sealed and then transferred to a cold storageunit, operating at a temperature above freezing, for a period of atleast 24 hours. The solution may then be dispensed and placed intopatches or other embodiments of the invention.

Example 17

TABLE 28 At least one embodiment of the invention includes: MaterialAmount Distilled Water 0.4 gallons Vegetable Glycerin 4.5 poundsL-Carnitine 4 grams AHK-Cu 150 mg Zinc Gluconate 1 gram Colloidal Copper20 ppm 50 ml Malic Acid, Citric Acid As needed to adjust pH PotassiumSorbate 1 gram

A double helix conductor as described in U.S. Pat. No. 8,653,925,entitled “Double Helix Conductor”, to Schmidt, is setup on a fixture andis of such size that a glass vessel containing 1 gallon of water fitsinside the center opening of the double helix conductor. The water isthen treated for a period of 24 hours in accordance with the teachingsof this invention prior to being used in the process below.

According to at least one embodiment of the invention, the containerbelow is setup using a lily impeller or other mixing blade such that thewater-based solution below will vortex as it is mixed.

A clean and dry container is placed on a scale, having a capacity of atleast 1 gallon. Glycerin is dispensed into the container and measured tobe 4.5 pounds. Distilled water is then added to the container in theamount of 0.4 Gallons. The contents are then mixed for 1 minute until byvisual inspection a uniform mixture has been obtained. Optionally, amagnetic mixer may be used, and the mixer is left on for the fullduration of the processing. After the glycerin and water have mixedtogether, the L-Carnitine is measured on a scale to 4 grams and thenadded; this is allowed to mix for 1 minute. AHK-Cu is then added to thecontainer in the amount of 150 mg, and this is allowed to mix for 1minute. Zinc Gluconate is measured to the amount of 1 gram, and this isallowed to mix for 1 minute. Colloidal Copper is measured to 50 ml andthen added to the container and mixed for 1 minute. At this point MalicAcid and Citric Acid may be introduced to pH adjust and balance thesolution as needed. 1 gram of Potassium Sorbate is then added andallowed to mix for 5 minutes. The solution is then mixed for anadditional 10 minutes or until a uniform solution has been formed, withno solids in the solution. This will make about 1 gallon of solution.This container is then sealed and then transferred to a cold storageunit, operating at a temperature above freezing, for a period of atleast 24 hours. The solution may then be dispensed and placed intopatches or other embodiments of the invention.

Example 18

TABLE 29 At least one embodiment of the invention includes: MaterialAmount Distilled Water 0.4 gallons Vegetable Glycerin 4.5 poundsL-Carnitine 4 grams AHK 150 mg Zinc Gluconate 1 gram Colloidal Copper 20ppm 50 ml Malic Acid, Citric Acid As needed to adjust pH PotassiumSorbate 1 gram

A double helix conductor as described in U.S. Pat. No. 8,653,925,entitled “Double Helix Conductor”, to Schmidt, is setup on a fixture andis of such size that a glass vessel containing 1 gallon of water fitsinside the center opening of the double helix conductor. The water isthen treated for a period of 24 hours in accordance with the teachingsof this invention prior to being used in the process below.

According to at least one embodiment of the invention, the containerbelow is setup using a lily impeller or other mixing blade such that thewater-based solution below will vortex as it is mixed.

A clean and dry container is placed on a scale, having a capacity of atleast 1 gallon. Glycerin is dispensed into the container and measured tobe 4.5 pounds. Distilled water is then added to the container in theamount of 0.4 Gallons. The contents are then mixed for 1 minute until byvisual inspection a uniform mixture has been obtained. Optionally, amagnetic mixer may be used, and the mixer is left on for the fullduration of the processing. After the glycerin and water have mixedtogether, the L-Carnitine is measured on a scale to 4 grams and thenadded; this is allowed to mix for 1 minute. AHK is then added to thecontainer in the amount of 150 mg, and this is allowed to mix for 1minute. Zinc Gluconate is measured to the amount of 1 gram, and this isallowed to mix for 1 minute. Colloidal Copper is measured to 50 ml andthen added to the container and mixed for 1 minute. At this point MalicAcid and Citric Acid may be introduced to pH adjust and balance thesolution as needed. 1 gram of Potassium Sorbate is then added andallowed to mix for 5 minutes. The solution is then mixed for anadditional 10 minutes or until a uniform solution has been formed, withno solids in the solution. This will make about 1 gallon of solution.This container is then sealed and then transferred to a cold storageunit, operating at a temperature above freezing, for a period of atleast 24 hours. The solution may then be dispensed and placed intopatches or other embodiments of the invention.

Example 19

TABLE 30 At least one embodiment of the invention includes: MaterialAmount Distilled Water 0.4 gallons Vegetable Glycerin 4.5 poundsL-Carnitine 4 grams L-Alanine 400 mg AHK-Cu 150 mg Zinc Gluconate 1 gramColloidal Copper 20 ppm 50 ml Malic Acid, Citric Acid As needed toadjust pH Potassium Sorbate 1 gram

A double helix conductor as described in U.S. Pat. No. 8,653,925,entitled “Double Helix Conductor”, to Schmidt, is setup on a fixture andis of such size that a glass vessel containing 1 gallon of water fitsinside the center opening of the double helix conductor. The water isthen treated for a period of 24 hours in accordance with the teachingsof this invention prior to being used in the process below.

According to at least one embodiment of the invention, the containerbelow is setup using a lily impeller or other mixing blade such that thewater-based solution below will vortex as it is mixed.

A clean and dry container is placed on a scale, having a capacity of atleast 1 gallon. Glycerin is dispensed into the container and measured tobe 4.5 pounds. Distilled water is then added to the container in theamount of 0.4 Gallons. The contents are then mixed for 1 minute until byvisual inspection a uniform mixture has been obtained. Optionally, amagnetic mixer may be used, and the mixer is left on for the fullduration of the processing. After the glycerin and water have mixedtogether, the L-Carnitine is measured on a scale to 4 grams and thenadded; this is allowed to mix for 1 minute. L-Alanine is measured to 400mg and then added and mixed for 1 minute. AHK-Cu is then added to thecontainer in the amount of 150 mg, and this is allowed to mix for 1minute. Zinc Gluconate is measured to the amount of 1 gram, and this isallowed to mix for 1 minute. Colloidal Copper is measured to 50 ml andthen added to the container and mixed for 1 minute. At this point MalicAcid and Citric Acid may be introduced to pH adjust and balance thesolution as needed. 1 gram of Potassium Sorbate is then added andallowed to mix for 5 minutes. The solution is then mixed for anadditional 10 minutes or until a uniform solution has been formed, withno solids in the solution. This will make about 1 gallon of solution.This container is then sealed and then transferred to a cold storageunit, operating at a temperature above freezing, for a period of atleast 24 hours. The solution may then be dispensed and placed intopatches or other embodiments of the invention.

Anti-Viral Embodiments

Embodiments may include, or be used with, copper glycinate as ananti-viral therapy or an anti-inflammatory or both. At least oneembodiment may be utilized to treat the novel coronavirus (COVID-19)through light mediated synthesis of copper peptide and mobilization ofcopper ions for example. Benefits of this therapy include:

-   -   Produces rapid alterations in blood chemistry for powerful        antiviral effects    -   Large body of evidence to support efficacy    -   Simple to administer    -   Reduced risk of toxic side effects    -   Inexpensive    -   Large scale manufacturing already in place for immediate        deployment

Embodiments of the invention target viruses through use of embodimentsof the patch 100 described herein and as shown in FIG. 1, along withadministration of any form of bioavailable copper, for example copperglycinate 101, (or copper gluconate, copper sulfate, copper carbonate,colloidal copper, or any other form of bioavailable copper) in oneembodiment administered orally, in other embodiments via transdermalpatches (e.g., in embodiments with a combined transdermal patch if soequipped at 100 or via separate transdermal patch 102 a), or viainjection, combined with embodiments described herein for example thatare configured to light mediate the synthesis of peptide GHK that bindsto copper for producing powerful antiviral effects. Embodiments may alsoinclude an anti-inflammatory, either taken orally 102 b, or viatransdermal patch 102 a, wherein the anti-inflammatory may include anyCOX-2 inhibitor or any steroidal anti-inflammatory or any other type ofanti-inflammatory compound.

While copper has demonstrated the ability to inactivate viruses onsurfaces (Warnes et al., 2015), copper is also a naturally occurringcomponent of skin and connective tissue. In the human body, copper ionsbind to specific peptides that have important metabolic functions inhuman beings.

Copper ions appear to attack viruses in two different ways, using twodifferent types of ions. The first, Cu(II), attacks the capsid barrier(Manuel et al., 2015), and this starts with the virus's receptor sites,immediately limiting its ability to infect individuals even before virusdeath (Manuel et al., 2015). Damaging viral receptor sites have beenshown to decrease infectiousness within 2 min. in a Norovirus strand(Manuel et al., 2015).

The second ion Cu(I) goes after the genome (Warnes et al., 2015). Itappears that one of the nucleic acids forms covalent bonds with copper,and in the process, divides the genome into pieces (Borkow et al.,2009). It appears that these nucleotides can occur as often as everythree nucleotides (Borkow et al., 2009). This means that the genomedivides into progressively smaller sections over time (Warnes et al.,2015). This has been seen to start within 15 minutes and leaves noviable virus by 2 hrs (Manuel et al., 2015). The DNA damage was found tostill occur with nanoparticles of copper, and not just with solidobjects (Fujimori et al., 2012). It also means that the genomicinformation will not be available for other viruses to integrate andmutate (Warnes et al., 2015).

Copper has a long history of use in medicine, starting with thepurification of drinking water and burns (Borkow et al., 2009.) It hascontinued to be used for purification of water, including use inhospitals to prevent legionnaires disease (Borkow et al., 2009). It alsohas EPA approval for use as an antimicrobial surface (Borkow et al.,2009).

“Copper has previously been implicated in the regulation of immuneresponses. (Hu Frisk et al., 2017).” There are studies demonstrating itsability to kill a number of different viruses, including HIV and Polio(Borkow et al., 2009). The CDC has recently pre-released information ona study completed in March 2020 on the lifespan of COVID-19 on differentsurfaces (van Doremalen et al., 2020). This included the lifespan oncopper, where it was completely dead within 4 hours (van Doremalen etal., 2020.)

A 2015 study found that the “ . . . immune system responds to infectionswith M. tuberculosis by overloading the phagosome with copper and zinc .. . (Neyrolles et al., 2015).” It should also be noted that, aside fromdecreasing the microbial burden itself, copper also appears to have anantimicrobial effect on its surroundings, and one which has been testedand remained consistent for 21 months (Schmidt et al., 2012). “Thelevels of antimicrobial activity of the metallic copper surfaces wereequivalent throughout the course of the trial (Schmidt et al., 2012).”“The most surprising finding was the 64% decrease in MB between thepreintervention and intervention phases in the control rooms (Schmidt etal., 2012).”

In an article published in the New England Journal of Medicine on Mar.17, 2020:

-   -   Aerosol and Surface Stability of SARS-CoV-2 as Compared with        SARS-CoV-1    -   https://www.nejm.org/doi/10.1056/NEJMc2004973    -   On copper, no viable SARS-CoV-2 was measured after 4 hours, and        no viable SARS-CoV-1 was measured after 8 hours.

In other research from the University of Southampton, evaluation of theability of copper to immobilize viruses produced significant results:

-   -   Using copper to prevent the spread of respiratory viruses    -   https://www.sciencedaily.com/releases/2015/11/151110102147.htm    -   New research from the University of Southampton has found that        copper can effectively help to prevent the spread of respiratory        viruses, which are linked to severe acute respiratory syndrome        (SARS) and the Middle East respiratory syndrome (MERS).

While this research points to the use of antimicrobial copper forinactivating viruses on a surface, embodiments of the invention seek toproduce the same effect within the human body. The following studyindicates that this is possible:

-   -   Mechanism of Copper-Mediated Inactivation of Herpes Simplex        Virus    -   https://aac.asm.org/content/aac/41/4/812.full.pdf    -   This study concluded that “The sensitivity exhibited by HSV to        Cu(II) and reducing agents, particularly ascorbate, might be        useful in the development of therapeutic antiviral agents        (Sagripanti et al., 1997).”

Embodiments of the invention may utilize a suitable efficacious amountof supplemental copper (such as 2 mg copper glycinate, twice daily)along with embodiments of the invention that produce light-mediatedincrease of GHK-Cu, a natural copper peptide.

GHK is a simple peptide that has a very high affinity for copper. GHK-Cunaturally occurs in the human body but declines with age (Pickart &Margolina, 2018). GHK-Cu has a number of significant beneficial effectson human beings such as:

-   -   improved energy metabolism and immune function    -   improves wound healing and tissue regeneration    -   possesses DNA repair, antioxidant, and anti-inflammatory effects    -   regulation of GABA for improved sleep    -   increases cellular stemness, secretion of trophic factors by        mesenchymal stem cells    -   increased expression of P63 for increased proliferation of stem        cells

However, perhaps the most profound attribute of GHK-Cu is its ability tomodulate gene expression, resetting thousands of genes to a moreyouthful state (Pickart et al., 2015; Pickart & Margolina, 2018).

-   -   Regenerative and Protective Actions of the GHK-Cu Peptide in the        Light of the New Gene Data    -   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073405/

As a result of this attribute of GHK-Cu, it has been discovered in priorresearch that improvements in immune response, reduction in inflammatorymarkers, facilitation in the repair of lung tissue from acute lunginjury, and general wound healing all improve. “The use of GHK-Cu inmice protected their lung tissue from induced acute lung injury (ALI)and suppressed the infiltration of inflammatory cells into the lung. TheGHK-Cu also increased superoxide dismutase (SOD) activity whiledecreasing TNF-1 and IL-6 production through the blocking activation ofNFκB's p65 and p38 MAPK (mitogen activated protein kinase) (Pickart &Margolina, 2018).” Improving these factors would be of tremendous valuein the event of a viral infection that causes lung inflammation,destruction, and organ failure.

To rapidly elevate GHK-Cu, at least one embodiment of the invention,namely a wearable, nanotechnology device that is applied to thepatient's skin is utilized. Embodiments of the invention, powered bybody heat, reflect specific wavelengths of light to the surface of theskin, stimulating the production of GHK-Cu, instead of providing copperpeptide by injection or oral supplementation. The effect is known asphotobiomodulation. Embodiments have been tested and show that GHK iselevated to significance within the first 24 hours of application to theskin. The blood samples were processed according to the original thesisof Dr. Pickard. There was a significant increase in GHK in the blood,which was seen at 24 hours, at the level of p<0.0098. A significantincrease in GHK-Cu in the blood was also seen at 7 days at the level ofp<0.0137.

It will be apparent to those skilled in the art that numerousmodifications and variations of the described examples and embodimentsare possible in light of the above teaching. The disclosed examples andembodiments are presented for purposes of illustration only. Otheralternate embodiments may include some or all of the features disclosedherein. Therefore, it is the intent to cover all such modifications andalternate embodiments as may come within the true scope of thisinvention.

What is claimed is:
 1. A wearable phototherapy system configured to beapplied to a subject's body to provide a beneficial effect for thesubject selected from a group consisting of activation of stem cells, animprovement in energy, an elevation of antioxidants, a reduction ininflammation, an elevation of collagen production, an improvement inwound healing, an increase in strength, an increase in stamina, a relieffrom pain and an improvement in strength endurance, the apparatuscomprising: a non-transdermal container configured to provide abeneficial biological effect, wherein said non-transdermal containercomprises matter that comprises at least one Left-Handed moleculecomprising at least one Left-Handed organic molecule or at least oneLeft-Handed inorganic molecule or both said at least one Left-Handedorganic molecule and said at least one Left-Handed inorganic molecule,wherein said at least one Left-Handed molecule further comprises amaterial pre-selected configured to interact with infrared light emittedby said subject's body; and, at least one phototherapy layer comprisingglycyl-L-histidyl-Lysine (GHK) or copper binding peptideglycyl-L-histidyl-Lysine (GHK-Cu) or alanyl-L-histidyl-L-Lysine (AHK) orcopper binding peptide alanyl-L-histidyl-L-Lysine (AHK-Cu), or anycombination thereof; wherein, via said at least one phototherapy layer,the matter in the non-transdermal container is configured to reflect oremit specific wavelengths of light into said subject's body after saidmatter is stimulated by said infrared light emitted by said subject'sbody wherein said specific wavelengths of light elevate levels of copperbinding peptide glycyl-L-histidyl-Lysine (GHK-Cu) in said subject'sbody; wherein the non-transdermal container is configured to couple tothe subject's body and prevent the at least one Left-Handed moleculefrom direct contact with the subject's body.
 2. The system of claim 1,wherein said non-transdermal container further comprises one or more ofat least one amino acid, at least one amino acid derivative, sodiummetasilicate, zinc gluconate, colloidal copper.
 3. The system of claim1, wherein to provide the beneficial effect of increase in strength oran improvement in strength endurance, the Left-Handed molecule is anamino acid, wherein the amino acid is selected from the group consistingof L-Arginine, L-Carnitine, Acetyl-L-Carnitine, L-Glutamine,L-Methionine, L-Ornithine, and L-Taurine.
 4. The system of claim 1,wherein to provide the beneficial effect of increase in strength or animprovement in strength endurance, the Left-Handed molecule is an aminoacid selected from L-Carnitine and Acetyl-L-Carnitine.
 5. The system ofclaim 1, wherein the non-transdermal container further comprises anenclosure, wherein the enclosure is made of a plastic film selected fromthe group consisting of polyethylene, polypropylene, AcrylonitrileButadiene Styrene (ABS), plexiglass, polycarbonate, light polarizingfilm, and linear low-density film.
 6. The system of claim 1, wherein thenon-transdermal container further comprises an enclosure, wherein theenclosure further comprises or couples with one or more adhesiveportions to permit attachment to the subject's body.
 7. The system ofclaim 1, wherein the said non-transdermal container further comprisesone or more additives that are selected from a group consisting ofglycerin, d-calcium pantothenate, sorbitol, propylparaben, potassiumsorbate, methylparaben, and colloidal gold.
 8. The system of claim 1,wherein the said non-transdermal container is a patch constructed inlayers, the layers comprising one or more of a plastic film as anenclosure, a light polarizing film as said enclosure, a polyester fabricas a substrate, water, L-Carnitine, glycerin, d-calcium pantothenate,sorbitol, propylparaben, potassium sorbate, and methylparaben.
 9. Thesystem of claim 1, wherein said at least one phototherapy layercomprises a first phototherapy layer and a second phototherapy layer.10. The system of claim 9, wherein said first phototherapy layer andsaid second phototherapy layer are one or more of layered on top of eachother, coupled directly or indirectly, layered as concentric rings. 11.The system of claim 9, wherein via said first phototherapy layer andsaid second phototherapy layer, the non-transdermal container reflectsdifferent wavelengths of light from each layer of said firstphototherapy layer and said second phototherapy layer.
 12. The system ofclaim 1, wherein the non-transdermal container further comprises atleast one ball or bead.
 13. The system of claim 1, further comprising atransdermal container, wherein the transdermal container is coupled tosaid non-transdermal container.
 14. The system of claim 1, furtherconfigured to provide an anti-viral effect, said system furthercomprising bioavailable copper, copper gluconate, copper sulfate, coppercarbonate, colloidal copper, copper glycinate, or any combinationthereof applied to said subject's body via a pill or via an injection.15. The system of claim 1, further comprising an anti-inflammatoryapplied to said subject's body via a pill or via a transdermal containercoupled to said non-transdermal container.
 16. The system of claim 13,wherein said transdermal container comprises at least one ofbioavailable copper, copper gluconate, copper sulfate, copper carbonate,colloidal copper, and copper glycinate.